

CURRICULUM VITAE

02/15/2018

NAME: Sheldon H. Preskorn, M.D.

CITIZENSHIP: United States of America

Addresses: Research - Kansas University – Wichita Clinical Trial Unit

Education - Kansas University School of Medicine – Wichita
1010 N. Kansas
Wichita KS 67214

WEBSITE: www.preskorn.com

MEDICAL

SCHOOL: University of Kansas, Kansas City, Kansas (M.D., 1974)

POSTGRADUATE:

Pathology Residency,
University of Kansas Medical Center (UKMC) Kansas City, Kansas, 1973-1975
Rotating Internship, Internal Medicine/Psychiatry
UKMC, Kansas City, Kansas, 1975-1976
Psychiatry Residency,
Washington University School of Medicine, St. Louis, Missouri, 1976-1978

ACADEMIC APPOINTMENTS:

Professor, Department of Psychiatry and Behavioral Sciences,
University of Kansas School of Medicine (UKSM), Wichita, Kansas, 2007-Present
Professor and Chairman, Department of Psychiatry and Behavioral Sciences,
University of Kansas School of Medicine (UKSM), Wichita, Kansas, 1999-2007
Professor and Vice Chairman, Department of Psychiatry,
UKSM, Wichita, Kansas, 1985-1999
Professor of Psychiatry and Pharmacology,
Washington University School of Medicine, St. Louis, Missouri, 1984-1985
Associate Professor of Psychiatry and Pharmacology Toxicology & Therapeutics,
UKSM, Kansas City, Kansas, 1981-1984
Assistant Professor of Psychiatry and Pharmacology Toxicology & Therapeutics,
UKSM, Kansas City, Kansas, 1978-1981
Assistant Instructor in Psychiatry,
Washington University School of Medicine, St. Louis, Missouri, 1976-1978

DIRECTORSHIP and PROFESSIONAL POSITIONS:

Research psychiatrist, Laureate Institute for Brain Research, 2012 - 2016
Tulsa OK
Chief Science Officer, Kansas University – Wichita Clinical Trials Unit, 2011 –
8911 E. Orme Ste. B Wichita, Kansas 67207
President & CEO, Clinical Research Institute, 2003-2010
201 S. Hillside Wichita, Kansas 67211 & 8911 E. Orme Ste. B Wichita, Kansas 67207
President and Medical Director, Psychiatric Research Institute, 1987-2003
Via Christi Regional Medical Center, Wichita, Kansas
Director, Outpatient Clinic Department of Psychiatry,

UKSM, Wichita, Kansas, 1991-1999
Chief, Psychiatry Service,
Wichita Veterans Administration Medical Center, Wichita, Kansas, 1985-1991

LICENSURE:

Permanent Kansas Medical License # 4-6344
Permanent Missouri Medical License # 00101337
Permanent Oklahoma Medical License # 29510

CONSULTANTSHIP:

Menninger Foundation, Topeka, Kansas, 1992-1998.
Food and Drug Administration, on specific topics or various occasions since 1994 -

AWARDS:

Top reviewer for Journal of Clinical Psychiatry, 2015
Kansas University Medical Center Research Institute Faculty Research Investigator Award, 2013
Kansas University Medical Center Research Institute Life-time Mentorship Award, 2013
Circle of Honor – for top 2% of all reviewers, Journal of Clinical Psychiatry, 2012
Numerous nominations for Top Doctors in Psychiatry in most years from 2008 – present
Who's Who in America, 2009
America's Top Psychiatrist, 2008
Foxington Who's Who Directory of Executives and Professionals, 2000
National Registry of Who's Who, Life Member, 2000
The Best Doctors in America, 4th Edition, 1998
American Psychiatric Assoc., Nancy C.A. Roeske, M.D Certificate of Excellence in Medical Student Education, 1998
National Alliance for the Mentally Ill, Exemplary Psychiatrist Award, 1993
The Mental Health Association in Kansas, 1989
Alliance for Mentally Ill in Sedgwick County, 1988
Research Scientist Development Award (NIMH), 1980-1985
American Academy of Clinical Psychiatry, Clinical Research Award, 1984
University of Kansas College of Health Sciences Research Award, 1983
American Academy of Clinical Psychiatry Annual Research Award, 1982
A.E. Bennett Neuropsychiatric Research Foundation Award, 1978
Roche Laboratory Award for Neuroscience, 1978
Mead-Johnson Award for Overall Excellence in Research, 1978
Walter C. Menninger Neuropsychiatry Award, 1978
Outstanding Young Men of America, 1977 and 1982
KUMC Psychiatric Housestaff Research Award, 1976
KUMC Pathology Housestaff Research Award, 1975
Chester M. Goodwin Award for Neurological Research, 1971
Who's Who in American Colleges and Universities, 1969

FELLOWSHIPS:

Maurice Falk Fellowship, 1975-1978
University of Kansas Research Fellowship, 1971
Wichita State University (WSU) Research Assistantship, 1970
WSU Honors Fellowship, 1969-1970

CERTIFICATION:

Psychiatry plus Geriatric qualifications, American Board of Psychiatry and Neurology, 1997
Diplomat, American Board of Psychiatry and Neurology, 1981
Diplomat, National Board of Medical Examiners, 1975

EDITORIAL BOARDS:

Associate Editor, Journal of Clinical Psychiatry, 2001-Present
Associate Editor, Journal of Clinical Psychopharmacology, 2000-Present
Contributing Editor, Journal of Psychiatric Practice, (formerly JPPBH) 2000-Present
Contributing Editor, Journal of Practical Psychiatry and Behavioral Health, 1995-1999
Preskorn SH: Associate Editor, Current Psychiatry, June 2003-Present
American Hospital Formulary Service Drug Information, 1998
Associate Editor, Journal of Clinical Psychiatry, 1978-1988

MAJOR RESEARCH INTEREST:

Psychopharmacology, neuroscience, affective/anxiety disorders

GRANTS:

Continuous funding since 1978. Supplemental report available.

NIH research network participation

These are competitive research networks established by the National Institute of Health involving principally first tier academic research centers around the country to study high interest research needs:

Regional director, NIMH Sequence Treatment Alternative to Relieve Depression (STAR*D) study (14 sites in US)
Associate regional director, NIMH Clinical Antipsychotic Treatment Intervention Effectiveness (CATIE) study (30 sites)
Regional principal investigator, NIMH Depression Trial Network (14 sites in the US)
Regional subinvestigator, NIMH Schizophrenia Trial Network (20 sites in the US)
Regional principal investigator, NIMH MATRICS Test Battery network, (5 sites in the US)
Regional principal investigator, NIMH RAPID Network (12 sites in the US)
Regional principal investigator, NINCDS NeuroNext network (15 sites in the US)
Regional principal investigator, Stanley Medical Research Institute VISTA network (12 sites in US)

REVIEWER FOR:

American Hospital Formulary Service Drug Information Monographs
American Journal of Geriatric Psychiatry
American Journal of Primatology
American Journal of Psychiatry
Annals of Pharmacotherapy
Archives of General Psychiatry
Biological Psychiatry
Bipolar Disorders
Clinical Pharmacokinetics
CNS Drugs
Currents in Affective Illness
Depression and Anxiety
Drug and Aging Journal

Drug Evaluations
Drugs
European Journal of Pharmacology
General Hospital Psychiatry
Geriatric Agitation Guidelines
Geriatric Psychiatry
International Journal of Neuropsychopharmacology
International Journal of Neuropsychiatry
International Journal of Psychiatry in Medicine
Journal of Affective Disorders
Journal of Clinical Psychiatry – top reviewer in 2015
Journal of Clinical Psychopharmacology
Journal of Neuropsychiatry & Clinical Neurosciences
Journal of Pharmaceutical Sciences
Journal of Pharmacology and Experimental Therapeutics
Journal of Pharmacy Technology
Journal of Psychiatric Practice
Journal of Psychopharmacology
Journal of the American Medical Association
Life Sciences
Mayo Clinic Proceedings
Neuropharmacology
Neuropsychopharmacology
Pharmacoeconomics
Psychiatric Times
Psychometrics
Psychopharmacology
Science
Therapeutics Bulletin

REVIEW COMMITTEES:

Ad hoc consultant, Translational Research and Experimental Therapeutics Programs, NIMH, 2015 - present
Panel Member, Center for Scientific Review, NIMH Special Emphasis Panel, 1999 - 2005
Panel Member, Center for Scientific Review, NIH Study Sect.-Genetic Sciences, 1999
Member, International Advisory Board for the Guidelines in Depression, 1998–2000
Member, Via Christi Institutional Review Board, 1989-Present
Moderator- Faculty, APA. Physician Awareness Program, 1987-1989
Reviewer Canadian Psychiatric Research Foundation
Reviewer (Member), Wesley Foundation Scientific Advisory Panel, 1987-1989
Reviewer (ad hoc), VA Merit Rev. Mental Health & Behavioral Science Comm., 1985
Reviewer (ad hoc), Nat'l Inst. Neurological & Communicative Disorders & Stroke (NINCDS) study section on Spinal Cord Trauma Centers, 1983 and 1987
Reviewer (ad hoc) National Science Foundation Neuropharmacology Section, 1983-1987
Reviewer (ad hoc), NIMH Psychopharmacological, Biological, and Physical Treatments Research Review Committee (TDA2), 1986
Member, FDA Psychopharmacologic Drugs Advisory Committee, 1982-1986
Reviewer (ad hoc), NIMH Mental Health Behavioral Science Research Review 1984

SOCIETIES:

American College of Neuropsychopharmacology, 2016
International Society for Affective Disorders, 2001-2002

American Psychopathological Association, Fellow, 1989
 American Psychiatric Association, Member, 1979; Fellow, 1987, Distinguished Fellow, 2003
 Society of Neuroscience, Member 1978; President 1981-1982; Local Chapter Secretary/Treasurer 1980
 American Society of Clinical Pharmacology and Therapeutics, Member, 1979
 Society of Biological Psychiatry, Member, 1978
 Alpha Omega Alpha, Member, 1973
 American Medical Association, Member 1971
 Phi Kappa Phi, Member, 1970
 Omicron Delta Kappa, President, 1969
 WSU Honors Society, Member 1969

ORGANIZATIONAL OFFICES:

Pharmacy, Therapeutics and Safety Committee, 1998-2000
 Member, Sedgwick County Task Force on Suicide Prevention, 2001-2006
 Scientific Advisor, MHA of So. Central Kansas, 2001-2006
 NIMH Outreach & Education, 2000-P2005
 Sedgwick County Alliance for Mentally Ill, 1996-Present
 Advisory Committee, Kansas Alliance for the Mentally Ill, 1993-Present
 Member, University of Kansas School of Medicine Research Committee, 1992-1994
 Member, Board of Directors, Project Awareness for Major Mental Illness, 1990-Present
 Founding President, Project Awareness for Major Mental Illness, 1990-1995
 Member, Scientific Program Committee for American Society of Clinical Pharmacology and Therapeutics, 1983-1985
 Chairman, KUMC Faculty & Student Affairs Committee, 1983-1984
 Member, Governor's Advisory Commission on Mental Health and Retardation Services and Community Mental Health Programs, State of Kansas, 1979-1984
 Member, American Psychiatric Association (APA) Program Committee (Nat'l), 1978-1982
 Chairman, APA Subcommittee on New Research, 1980-1982
 Member, American Psychiatric Association Council-Research & Development, 1976-1978
 Member, American Psychiatric Association Task Force Tardive Dyskinesia, 1976-1979
 Member, Continuing Education Committee for Kansas Psychiatric Society, 1980-1982
 Member, KUMC Human Studies Research Committee, 1979-1984
 Member, KUMC Peer Utilization Review Committee, 1978-1980
 Representative, KUMC Housestaff Association, 1976
 Representative, Association of American Medical Colleges, 1971-1973
 Treasurer, KUMC Chapter (student) of the KS Medical Society, 1970-1971
 President/Administrative/Executive Coordinator, WSU Student Union Activities Board, 1969-1970
 Educational/Cultural Coordinator, WSU Student Union Activities Board, 1968-1969
 Chairman, Wichita Film Society, 1967-1968

VISITING PROFESSOR/LECTURER:

Presented at meetings and/or universities in the following cities on one or more occasions:

Foreign Countries

Aruba	Rhodes, Greece
Buenos Aires, Argentina	
Brisbane, Australia	
Hobart, Australia	Budapest, Hungary
Melbourne, Australia	Goa India
Sydney, Australia	Jerusalem, Israel
Vienna, Austria	Cagliari, Italy

Bahamas	Florence, Italy
Barbados	Palermo, Italy
Brussels, Belgium	Rome, Italy
Hamilton, Bermuda	Venice, Italy
Rio de Janeiro, Brazil	Kyoto, Japan
San Paulo, Brazil	Seoul, Korea
Edmunton, Canada	Mexico City, Mexico
Halifax, Canada	Acapulco, Mexico
Hamilton, Canada	Monte Carlo, Monaco
London, Canada	Amsterdam, Netherlands
Montreal, Canada	Auckland, New Zealand
Regina, Canada	Oslo, Norway
Toronto, Canada	Trondheim, Norway
Saskatchewan, Canada	Tromso, Norway
Vancouver, Canada	Lisbon, Portugal
Winnipeg, Canada	Las Croabas, Puerto Rico
Santiago, Chile	Ponce, Puerto Rico
Beijing, China	
Guangzhou, China	San Juan, Puerto Rico
Hanzhou, China	Glasgow, Scotland
Hong Kong, China	Al-Khobar, Saudi Arabia
Lanzhou, China	Damman, Saudi Arabia
Shanghai, China	Jeddah, Saudi Arabia
Bogata, Columbia	
Copenhagen, Denmark	Riyadh, Saudi Arabia
Odense, Denmark	Cape Town, South Africa
Alexandria, Egypt	Johannesburg, South Africa
Cairo, Egypt	Barcelona, Spain
Oxford, England	Madrid, Spain
London, England	Linkoping, Sweden
Cannes, France	Lund, Sweden
Nice, France	Stockholm, Sweden
Paris, France	Basel, Switzerland
Berlin, Germany	Berne, Switzerland
Dresden, Germany	Geneva, Switzerland
Frankfurt, Germany	Lausanne, Switzerland
Giessen, Germany	Zurich, Switzerland
Hamburg, Germany	Taipei, Taiwan
Hannover, Germany	Trinidad
Marburg, Germany	Anoyla, Turkey
Muenster, Germany	Istanbul, Turkey
Tuebingen, Germany	Dubai, United Arab Emirates
Athens, Greece	Montevideo Uruguay

United States of America

Baylor University
 Boston University
 Bowman University
 Case Western Reserve University

University of California-Sacramento
 University of California-San Francisco
 University of California-San Diego
 University of Colorado

Chicago University
Cleveland Clinic
Columbia University
Cornell University
Creighton University
Duke University
East Carolina University
George Washington University
Georgetown University
Harvard University-Beth Israel Hospital
Harvard University-Massachusetts Mental Health Center
Harvard University-Massachusetts General Hospital
Harvard University-McLean Hospital
Henry Ford Hospital-Detroit
Howard University
John Hopkins University
Loma Linda University
Louisiana State University-Shreveport
Louisiana State University-New Orleans
Loyola University
Mayo Clinic
Medical College of Ohio
Medical College of South Carolina
Menninger Foundation
New York University
Northwestern University
Ohio State University
Oklahoma Department of Mental Health
Purdue University
Rush Presbyterian University
Southern Illinois University-Springfield
Southwestern Medical College-Dallas
St. Louis University
Stanford University
State University of New York-Albany
State University of New York-Buffalo
State University of New York-Stony Brook
Texas Tech University
Thomas Jefferson University
Tufts University
Tulane University
University of Alabama-Birmingham
University of Arizona
University of Arkansas
University of California-Davis
University of California-Irvine
University of California-Los Angeles

University of Connecticut-Institute of Living
University of Hawaii
University of Iowa
University of Kentucky
University of Louisville
University of Maine
University of Miami
University of Michigan
University of Minnesota
University of Mississippi
University of Missouri-Columbia
University of Missouri-Kansas City
University of Nebraska
University of Nevada-Las Vegas
University of Nevada-Reno
University of New Hampshire
University of New Jersey Dental
University of New Mexico
University of North Dakota
University of Ohio
University of Oklahoma-Oklahoma City
University of Oklahoma-Tulsa
University of Oregon
University of Pennsylvania
University of Pittsburg
University of South Dakota
University of South Florida
University of South Carolina-Columbia
University of Southern Alabama
University of Southern California
University of Tennessee
University of Texas-Austin
University of Texas-Galveston
University of Utah
University of Washington-Seattle
University of Washington-Spokane
University of Vermont
University of Virginia
University of Wisconsin
University of Wisconsin-Madison
University of Wisconsin-Milwaukee
University of Wisconsin Medical College
Vanderbilt University
Washington University
Wayne State University
Wichita State University

SUMMARIZED PUBLICATIONS:

Over 500 scientific and professional publications including 359 articles, 13 books, and 57 book chapters.

Per Google Scholar as of 7/14/18, h-index = 60 and i10-index = 225 with 30 articles cited 100 times or more including one article cited over 1300 times, a solo authored article cited over 300 times, a total of 13,848 citations since 1980 and 400 or more citations each year since 1997.

Principal topics have been basic and clinical psychopharmacology, psychiatric drug development, affective and anxiety disorders, and neuroscience.

ITEMIZED PUBLICATIONS:

Journal Articles

- (1) Hughes CW, Lewis Jr GA, Preskorn SH. A stereotaxic implant technique for the weanling rat. *Behav Res Meth & Instru* 1973; 5(3):283-284.
Ref ID: EN 5772
- (2) Watanabe I, Preskorn SH. Virus-cell interaction in oligodendroglia, astroglia and phagocyte in progressive multifocal leukoencephalopathy. An electron microscopic study. *Acta Neuropathol (Berl)* 1976; 36(2):101-115.
Ref ID: EN 3612
- (3) Heller-Bettinger I, Kepes JJ, Preskorn SH, Wurster JB. Bilateral altitudinal anopia caused by infarction of the calcarine cortex. *Neurology* 1976; 26(12):1176-1179.
Ref ID: EN 3611
- (4) Cunningham ME, Kishore PR, Rengachary SS, Preskorn SH. Progressive multifocal leukoencephalopathy presenting as focal mass lesion in the brain. *Surg Neurol* 1977; 8(6):448-450.
Ref ID: EN 3609
- (5) Penka WE, Edwards WD, Preskorn SH, Kepes JJ. The deadliest rupture: Idiopathic muscular hypertrophy of the esophagus. *J Kansas Med Soc* 1977; 78(6):269-275.
- (6) Preskorn SH, Denner LJ. Benzodiazepines and withdrawal psychosis. Report of three cases. *JAMA* 1977; 237(1):36-38.
- (7) Preskorn SH, Edwards WD, Justesen DR. Retarded tumor growth and greater longevity in mice after fetal irradiation by 2450-MHz microwaves. *J Surg Oncol* 1978; 10(6):483-492.
- (8) Lewis GA, Preskorn SH, Hughes CW. Altered acetylcholinesterase activity (AChE) and maze performance of developing rats (*Rattus norvegicus*) following mesencephalic electrical brain stimulation. *Physiological Psychology* 1978; 6(1):53-56.
- (9) Biggs JT, Preskorn SH, Ziegler V, Rosen S, Meyer D. Dosage schedule and plasma levels of doxepin and desmethyldoxepin. *J Clin Psychiatry* 1978; 39(10):740-742.
- (10) Ziegler V, Biggs JT, Rosen S, Meyer D, Preskorn SH. Imipramine and desipramine plasma levels: relationship to dosage schedule and sampling time. *J Clin Psychiatry* 1978; 39(8):660-663.
- (11) Preskorn SH, Reveley A. Pseudohypoparathyroidism and capgras syndrome. *Br J Psychiatry* 1978; 133:34-37.
- (12) Preskorn SH, Abernethy DR, McKnelly Jr. WV. The use of saliva lithium determinations for monitoring lithium therapy. *J Clin Psychiatry* 1978; 39(10):756-758.
- (13) Preskorn SH, Hartman BK. The effect of tricyclic antidepressants on cerebral fluid dynamics. *Biol Psychiatry* 1979; 14(2):235-250.
- (14) Preskorn SH, Watanabe I. Progressive multifocal leukoencephalopathy: Cerebral mass lesions. *Surg Neurol* 1979; 12(3):231-234.
- (15) Othmer E, Powell B, Piziak VK, Preskorn SH. Prospective use of saliva lithium determinations to monitor lithium therapy. *J Clin Psychiatry* 1979; 40(12):525-526.

- (16) Preskorn SH, Hartman BK. Tricyclic antidepressants: New sites of action. *Behav Med* 1979; 6:30-33.
- (17) Preskorn SH, Hartman BK, Raichle ME, Clark HB. The effect of dibenzazepines (tricyclic antidepressants) on cerebral capillary permeability in the rat in vivo. *J Pharmacol Exp Ther* 1980; 213(2):313-320.
- (18) Preskorn SH, Hartman BK, Raichle ME, Swanson LW, Clark HB. Central adrenergic regulation of cerebral microvascular permeability and blood flow: Pharmacologic evidence. *Adv Exp Med Biol* 1980; 131:127-138.
- (19) Balderessarini R, Cole J, David J, Gardos G, Preskorn SH, Simpson G et al. Tardive dyskinesia: A task force report. *Am J Psychiatry* 1980; 137(10):1163-1172.
- (20) Preskorn SH, Leonard K, Hignite C. Liquid chromatography of amitriptyline and related tricyclic compounds. *J Chromatogr* 1980; 197:246-250.
- (21) Preskorn SH, Hartman BK, Clark HB. Long-term antidepressant treatment: Alterations in cerebral capillary permeability. *Psychopharmacology (Berl)* 1980; 70(1):1-4.
- (22) Preskorn SH, Schwin RL, McKnelly WV. Analgesic abuse and the barbiturate abstinence syndrome. *JAMA* 1980; 244(4):369-370.
- (23) Hughes CW, Preskorn SH. Consideration of physiologic mechanisms in animal models of "sudden death". *Omega* 1980; 11(2):113-118.
- (24) Preskorn SH, Madakasira S. Tricyclic antidepressants: Clinical use of plasma levels. *J Kansas Med Soc* 1981; 82(3):122-124, 134.
- (25) Clark HB, Hartman BK, Raichle ME, Preskorn SH, Larson KB. Measurement of cerebral vascular extraction fractions in the rat using intracarotid injection techniques. *Brain Res* 1981; 208(2):311-323.
- (26) Hartman BK, Swanson LW, Kaplan GP, Raichle ME, Preskorn SH, Clark HB. Anatomical evidence for central catecholaminergic innervation of the cerebral microvasculature. *J Cereb Blood Flow Metab* 1981; 1(1):S307-S308.
- (27) Preskorn SH, Irwin G, Simpson S, Friesen D. Modulation of cerebral fluid dynamics: Alpha and beta adrenergic mechanisms. *J Cereb Blood Flow Metab* 1981; 1(S1):S373-S374.
- (28) Irwin G.H., Preskorn SH. Simultaneous measurement of brain permeability and blood flow in the rat. *J Cereb Blood Flow Metab* 1981; 1[suppl 1]:S391-S392.
- (29) Preskorn SH, Irwin GH, Simpson S, Friesen D, Rinne J, Jerkovich G. Medical therapies for mood disorders alter the blood-brain barrier. *Science* 1981; 213(4506):469-471.
- (30) Weller RA, Weller EB, Preskorn SH. Clinical response and plasma imipramine levels in prepubertal depressed children. *World J Psychosynthesis* 1981; 13:9-13.
- (31) Glotzbach RK, Preskorn SH. Brain concentrations of tricyclic antidepressants: single-dose kinetics and relationship to plasma concentrations in chronically dosed rats. *Psychopharmacology* 1982; 78:25-27.
- (32) Irwin GH, Preskorn SH. A dual label radiotracer technique for the simultaneous measurement of cerebral blood flow and the single-transit cerebral extraction of diffusion-limited compounds in rats. *Brain Res* 1982; 249(1):23-30.
- (33) Preskorn SH, Simpson S. Tricyclic-antidepressant-induced delirium and plasma drug concentration. *Am J Psychiatry* 1982; 139(6):822-823.
- (34) Preskorn SH, Raichle ME, Hartman BK. Antidepressants alter cerebrovascular permeability and metabolic rate in primates. *Science* 1982; 217(4556):250-252.
- (35) Preskorn SH, Irwin HA. Toxicity of tricyclic antidepressants - kinetics, mechanism, intervention: a review. *J Clin Psychiatry* 1982; 43:151-156.
- (36) Clark HB, Hartman BK, Raichle ME, Preskorn SH, Larson KB. An intravenous technique for the measurement of cerebral vascular extraction fraction in the rat. *J Cereb Blood Flow Metab* 1982; 2(2):187-196.

- (37) Preskorn SH, Schreiber M, Hughes CW. Attitudes toward psychiatric consultation: Effect of training. *J Psychiatric Treat Eval* 1982; 4:313-316.
- (38) Weller EB, Weller RA, Preskorn SH, Glotzbach RK. Steady-state plasma imipramine levels in prepubertal depressed children. *Am J Psychiatry* 1982; 139(4):506-508.
- (39) Preskorn SH, Hartman BK, Irwin GH, Hughes CW. Role of the central adrenergic system in mediating amitriptyline-induced alteration in the mammalian blood-brain barrier in vivo. *J Pharmacol Exp Ther* 1982; 223(2):388-395.
- (40) Cantilena Jr LR, Irwin G, Preskorn SH, Klassen CD. The effect of diethyldithiocarbamate on brain uptake of cadmium. *Toxicol Appl Pharmacol* 1982; 63(3):338-343.
- (41) Madakasira S, Preskorn SH, Weller R, Pardo M. Single dose prediction of steady state plasma levels of amitriptyline. *J Clin Psychopharmacol* 1982; 2(2):136-139.
- (42) Preskorn SH, Weller E, Weller R. Depression in children: Relationship between plasma imipramine levels and response. *J Clin Psychiatry* 1982; 43(11):450-453.
- (43) Preskorn SH, Glotzbach RK. A liquid chromatographic method for quantitating amitriptyline in brain tissue. *Psychopharmacology (Berl)* 1982; 78(1):23-24.
- (44) Haemmerlie FM, Hughes CW, Preskorn SH. Psychology interns' view of the psychiatric consult. *J Psychiatric Treat Eval* 1983; 5:277-280.
- (45) Preskorn SH. Antidepressant response and plasma concentrations of bupropion. *J Clin Psychiatry* 1983; 44(5 Pt 2):137-139.
- (46) Weller EB, Preskorn SH, Weller RA, Croskell M. Childhood depression: Imipramine levels and response. *Psychopharmacol Bull* 1983; 19(1):59-62.
- (47) Preskorn SH, Hughes CW. Ethanol effects on brain concentrations of amitriptyline and the relationship to psychomotor function. *Psychopharmacology (Berl)* 1983; 80(3):217-220.
- (48) Weller EB, Weller RA, Preskorn SH. Depression in children: Effects of antidepressant therapy. *J Kansas Med Soc* 1983; 84(3):117-119.
- (49) Kent TA, Preskorn SH, Solnick JV, Irwin GH, Swartzman J, Goldberg S et al. Differential effects of central biogenic amines on cerebral blood flow and the blood-brain barrier. *J Cereb Blood Flow Metab* 1983; 3(1):S228-S229.
- (50) Preskorn SH, Weller E, Weller R, Glotzbach E. Plasma levels of imipramine and adverse effects in children. *Am J Psychiatry* 1983; 140(10):1332-1335.
- (51) Preskorn SH, Othmer SC. Evaluation of bupropion hydrochloride: The first of a new class of atypical antidepressants. *Pharmacotherapy* 1984; 4(1):20-34.
- (52) Weller R, Preskorn SH. Psychotropic drugs and alcohol: Pharmacokinetic and pharmacodynamic interactions. *Psychosomatics* 1984; 25(4):301-309. RM 1851
- (53) Ritchie KS, Preskorn SH. Mania induced by metoclopramide: Case report. *J Clin Psychiatry* 1984; 45(4):180-181.
- (54) Preskorn SH, Mac D. The implication of concentration-response studies of tricyclic antidepressants for psychiatric research and practice. *Psychiatr Dev* 1984; 3:201-222.
- (55) Weller E, Weller R, Fristad M, Preskorn SH. The dexamethasone suppression test in hospitalized prepubertal depressed children. *Am J Psychiatry* 1984; 141(2):290-291.
- (56) Hughes C, Kent T, Campbell J, Oke A, Croskell H, Preskorn SH. Cerebral blood flow and cerebrovascular permeability in an inescapable shock (learned helplessness) animal model of depression. *Pharmacol Biochem & Beh* 1984; 21(6):891-894.
- (57) Preskorn SH, Othmer SC. Bupropion: A monocyclic antidepressant. *J Clin Psychiatry* 1984; 2(5):23-26.

- (58) Cano SB, Generali JA, Letendre DE, Hastings MT, Preskorn SH. Evaluation of amitriptyline use by internists and psychiatrists. *Hosp Formul* 1984; 19:1131-1155.
- (59) Preskorn SH, Othmer SC, Lai CW, Othmer E. Tricyclic-induced electroencephalogram abnormalities and plasma drug concentrations. *J Clin Psychopharmacol* 1984; 4(5):262-264.
- (60) Preskorn SH, Kent TA, Glotzbach RK, Irwin GH, Solnick JV. Cerebromicrocirculatory defects in animal model of depression. *Psychopharmacology* 1984; 84:196-199.
- (61) Weller E, Weller R, Fristad M, Preskorn SH, Teare M. The dexamethasone suppression test in prepubertal depressed children. *J Clin Psychiatry* 1985; 46(12):511-513.
- (62) Kent T, Preskorn SH. A modified method for the simultaneous determination of regional single-transit brain extraction of diffusion-limited compounds and cerebral blood flow: Utilization of non-invasive measurement of transit time. *Brain Res* 1985; 335(2):251-255.
- (63) Preskorn SH, Mac D. Plasma levels of amitriptyline: Effect of age and sex. *J Clin Psychiatry* 1985; 46(7):276-277.
- (64) Kent TA, Yang R, Croskell H, Preskorn SH. Age effects on the cerebral circulation in the fisher-344 rat. *J Cereb Blood Flow Metab* 1985; 5 [suppl 1]:S145-S146.
- (65) Rubin E, Biggs JT, Preskorn SH. Nortriptyline pharmacokinetics and plasma levels: implications for clinical practice. *J Clin Psychiatry* 1985; 46(10):418-424.
- (66) Weller RA, Weller E, Fristad M, Cantwell M, Preskorn SH. A comparison of the cortisol suppression index and the dexamethasone suppression test in prepubertal children. *Am J Psychiatry* 1985; 142(11):1370-1372.
- (67) Kent T, Nagy G, Oke A, Preskorn SH, Adams R. Effect of CO₂ on a brain extracellular space marker and evidence of its neuronal modulation. *Brain Res* 1985; 342(1):141-144.
- (68) Kent T, Preskorn SH, Glotzbach RK, Irwin G. Amitriptyline normalizes tetrabenazine-induced changes in cerebral microcirculation. *Biol Psychiatry* 1986; 21(5-6):483-491.
- (69) Rubin EH, Preskorn SH, Hartman BK. The role of the central adrenergic system in the regulation of the cerebromicrocirculation. *Ann N Y Acad Sci* 1986; 462:224-231.
- (70) Preskorn SH, Weller E, Hughes C, Weller R. Plasma monitoring of tricyclic antidepressants: defining the therapeutic range for imipramine in depressed children. *Clin Neuropharmacol* 1986; 9[suppl 4]:265-267.
- (71) Weller E, Weller R, Fristad M, Cantwell M, Preskorn SH. Dexamethasone suppression test and clinical outcome in prepubertal depressed children. *Am J Psychiatry* 1986; 143(11):1469-1470.
- (72) Preskorn SH. Tricyclic antidepressant plasma level monitoring: An improvement over the dose-response approach. *J Clin Psychiatry* 1986; 47[suppl 1]:24-30.
- (73) Preskorn SH, Weller E, Hughes C, Weller R, Bolte K. Depression in prepubertal children: Dexamethasone nonsuppression predicts differential response to imipramine vs. placebo. *Psychopharmacol Bull* 1987; 23(1):128-133.
- (74) Ziegler D, Hurwitz A, Hassanein R, Kodanaz H, Preskorn SH, Mason J. Migraine prophylaxis. A comparison of propranolol and amitriptyline. *Arch Neurol* 1987; 44(5):486-489.
- (75) Preskorn SH, Goodwin D. Medical management of the depressed alcoholic patient. *Int J Psychiatry Med* 1987; 17(2):117-131.
- (76) Hughes C, Preskorn SH, Weller E, Weller R, Hassanein R. Imipramine vs. placebo studies of childhood depression: Baseline predictors of response to treatment and factor analysis of presenting symptoms. *Psychopharmacol Bull* 1988; 24(2):275-279.
- (77) Preskorn SH, Weller E, Jerkovich G, Hughes C, Weller R. Depression in children: Concentration-dependent CNS toxicity of tricyclic antidepressants. *Psychopharmacol Bull* 1988; 24(1):140-142.
- (78) Preskorn SH, Dorey RC, Jerkovich GS. Therapeutic drug monitoring of tricyclic antidepressants. *Clin Chem* 1988; 34(5):822-828.

- (79) Fristad M, Weller E, Weller R, Teare M, Preskorn SH. Self-report vs. biological markers in assessment of childhood depression. *J Affect Disord* 1988; 15:339-345.
- (80) Othmer SC, Othmer E, Preskorn SH, Mac D. Differential effect of amitriptyline and bupropion on primary and secondary depression: A pilot study. *J Clin Psychiatry* 1988; 49:310-312.
- (81) Dorey RC, Preskorn SH, Widener P. Results compared for tricyclic antidepressants as assayed by liquid chromatography and enzyme immunoassay. *Clin Chem* 1988; 34(11):2348-2351.
- (82) Bober J, Weller E, Weller R, Tait A, Fristad M, Preskorn SH. Correlation of serum and salivary cortisol levels in prepubertal school-aged children. *J Am Acad Child Adolesc Psychiatry* 1988; 27(6):748-750.
- (83) Preskorn SH, Bupp S, Weller E, Weller R. Plasma levels of imipramine and metabolites in 68 hospitalized children. *J Am Acad Child Adolesc Psychiatry* 1989; 28(3):373-375.
- (84) Preskorn SH. Tricyclic antidepressants: The whys and hows of therapeutic drug monitoring. *J Clin Psychiatry* 1989; 50[suppl 7]:34-42.
- (85) Hughes C, Preskorn SH. Depressive syndromes in children and adolescents: Diagnosis and treatment. *Ann Clin Psychiatr* 1989; 1(2):109-118.
- (86) Preskorn SH, Bupp S, Croskell H, Croskell M. Brattleboro rats exhibit normal PaCO₂-induced changes in cerebral microcirculation. *Biol Psychiatry* 1989; 25(5):648-653.
- (87) Preskorn SH, Jerkovich GS, Beber JH, Widener P. Therapeutic drug monitoring of tricyclic antidepressants: A standard of care issue. *Psychopharmacol Bull* 1989; 25(2):281-284.
- (88) Hughes CW, Preskorn SH, Weller E, Weller R, Hassanein R. A descriptive profile of the depressed child. *Psychopharmacol Bull* 1989; 25(2):232-237.
- (89) Yaylayan S, Weller E, Weller R, Fristad M, Preskorn SH. DST status and blood chemistries in prepubertal children. *Psychiatry Res* 1989; 29(2):215-219.
- (90) Preskorn SH, Katz S. Bupropion plasma levels: Intraindividual and interindividual variability. *Ann Clin Psychiatr* 1989; 1(1):59-61.
- (91) Martin R, Preskorn SH. Psychopharmacology - present and future. *Psychiatric Annals* 1990; 20(11):622.
- (92) Preskorn SH. The future and psychopharmacology: Potentials and needs. *Psychiatric Annals* 1990; 20(11):625-633.
- (93) Hughes C, Preskorn SH, Weller E, Weller R, Hassanein R, Tucker S. The effect of concomitant disorders in childhood depression on predicting treatment response. *Psychopharmacol Bull* 1990; 26(2):235-238.
- (94) Hughes C, Preskorn SH, Weller E, Weller R, Hassanein R, Tucker S. Follow-up of adolescents initially treated for prepubertal onset major depressive disorders with imipramine. *Psychopharmacol Bull* 1990; 26(2):244-248.
- (95) Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: Phenomenology, course, risk factors and role of therapeutic drug monitoring. *J Clin Psychopharmacol* 1990; 10(2):88-95.
- (96) Goldstein E, Kent B, Preskorn SH. Baclofen-Induced delirium: A case report. *Ann Clin Psychiatr* 1990; 2:223-224.
- (97) Preskorn SH, Silkey B, Beber JH, Dorey C. Antidepressant response and plasma concentrations of fluoxetine. *Ann Clin Psychiatr* 1991; 3(2):147-151.
- (98) Bupp S, Preskorn SH. The effect of age on plasma levels of nortriptyline. *Ann Clin Psychiatr* 1991; 3(1):61-65.
- (99) Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: Efficacy, safety and cost effectiveness. *J Clin Psychiatry* 1991; 52[suppl 6]:23-33.
- (100) Preskorn SH. Should bupropion dosage be adjusted based upon therapeutic drug monitoring. *Psychopharmacol Bull* 1991; 27(4):637-643.

- (101) Fristad M, Weller R, Weller E, Teare M, Preskorn SH. Comparison of the parent and child versions of the children's depression inventory (CDI). *Ann Clin Psychiatr* 1991; 3(4):341-346.
- (102) Preskorn SH, Fast GA. Tricyclic antidepressant induced seizures and plasma drug concentration. *J Clin Psychiatry* 1992; 53(5):160-162.
- (103) Preskorn SH, Burke M. Somatic therapy for major depressive disorder: Selection of an antidepressant. *J Clin Psychiatry* 1992; 53[suppl 9]:5-18.
- (104) Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. *Clin Pharmacol Ther* 1992; 52(5):479-486.
- (105) Drevets WC, Videen T, Preskorn SH, Price J, Carmichael S, Raichle M. A functional anatomical study of unipolar depression. *J Neurosci* 1992; 12(9):3628-3641.
- (106) Preskorn SH, Burke M, Fast GA. Therapeutic drug monitoring. Principles and practice. *Psychiatric Clinics of North America* 1993; 16(3):611-646.
- (107) Martin R, Preskorn SH. Special and innovative uses of benzodiazepines: introduction and raison d'etre. *Psychiatric Annals* 1993; 23(6):299-300.
- (108) Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. *Am J Med* 1993; 94 [suppl 5A]:2S-12S.
- (109) Horst WD, Preskorn SH. The role of benzodiazepines in the treatment of psychotic disorders. *Psychiatr Ann* 1993; 23(6):317-324.
- (110) Preskorn SH, Fast GA. Beyond signs and symptoms: The case against a mixed anxiety and depression category. *J Clin Psychiatry* 1993; 54[suppl 1]:24-32.
- (111) Preskorn SH. Sudden death and tricyclic antidepressants (TCA): A rare adverse event linked to high TCA plasma levels. *Nord J Psychiatry* 1993; 47 [suppl 30]:49-55.
- (112) Preskorn SH. The revolution in psychiatry. *Phi Kappa Phi Journal* 1993;22-25.
- (113) Ziegler D, Hurwitz A, Preskorn SH, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine: Pharmacokinetic and therapeutic effects. *Arch Neurol* 1993; 50:825-830.
- (114) Preskorn SH. Pharmacokinetics of antidepressants: Why and how they are relevant to treatment. *J Clin Psychiatry* 1993; 54 [suppl 9]:14-34.
- (115) Preskorn SH. Pharmacokinetics of psychotropic agents: Why and how they are relevant to treatment. *J Clin Psychiatry* 1993; 54[suppl 9]:3-7.
- (116) Hughes CW, Preskorn SH. Pharmacokinetics in child/adolescent psychiatric disorders. *Psychiatric Annals* 1994; 24(2):76-82.
- (117) Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. *J Clin Psychopharmacol* 1994; 14(2):90-98.
- (118) Preskorn SH. Targeted pharmacotherapy in depression management: Comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. *Int J Clin Pharmacol* 1994; 9[suppl 3]:13-20.
- (119) Preskorn SH. Update on antidepressant therapy. *J Clin Psychiatry* 1994; 55[suppl A]:98-100.
- (120) Preskorn SH. Antidepressant drug selection: Criteria and options. *J Clin Psychiatry* 1994; 55[suppl A]:6-24.
- (121) Burke MJ, Silkey B, Preskorn SH. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. *J Clin Psychiatry* 1994; 55(A):42-54, discussion 53-54, 98-100.
- (122) Weller R, Kapadia P, Weller E, Fristad M, Lazaroff L, Preskorn SH. Psychopathology in families of children with major depressive disorders. *J Affect Disord* 1994; 31:247-252.
- (123) Cunningham LA. Depression in the medically ill: Choosing an antidepressant. *J Clin Psychiatry* 1994; 55(9)[suppl A]:90-100.

- (124) Preskorn SH, Magnus R. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo finding and their implications for patient care. *Psychopharm Bull* 1994; 30(2):251-259.
- (125) Preskorn SH. Farmacoterapia no tratamento da depressao: farmacocinetica comparative da fluoxetina, paroxetina e sertralina. *Jornal Brasileiro De Psiquiatria* 1994; 43(2):69S-75S.
- (126) Preskorn SH, Lacey R. Polypharmacy: When is it rational? *J Prac Psych and Behav Hlth* 1995; 1:92-98.
- (127) Preskorn SH. Beyond DSM-IV: What is the cart and what is the horse? *Psychiatr Ann* 1995; 25(1):53-62.
- (128) Preskorn SH, Baker B. Outpatient management of the depressed patient. *Dis Mon* 1995; 41(2):73-140.
- (129) Preskorn SH. Advances in antidepressant pharmacotherapy. Part I. *Psych Times* 1995; June: 39-41.
- (130) Preskorn SH. Should rational drug development in psychiatry target more than one mechanism of action in a single molecule? *Int Rev Psychiatry* 1995; 7:17-28.
- (131) Preskorn SH. Advances in antidepressant pharmacotherapy. Part II. *Psych Times* 1995; July:14-16.
- (132) Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. *J Clin Psychiatry* 1995; 56[suppl 6]:12-21.
- (133) Lane R, Baldwin D, Preskorn SH. The SSRIs: Advantages, disadvantages and differences. *Journal of Psychopharmacology* 1995; 9[suppl 3]:163-178.
- (134) Preskorn SH, Lane R. Sertraline 50 mg daily: The optimal dose in the treatment of depression. *Int Clin Psychopharmacol* 1995; 10(3):129-141.
- (135) Catterson ML, Preskorn SH. Pharmacokinetics of selective serotonin reuptake inhibitors: Clinical relevance. *Pharmacol Toxicol* 1996; 78:203-208.
- (136) Preskorn SH. Introduction. Reducing the risk of drug-drug interactions: A goal of rational drug development. *J Clin Psychiatry* 1996; 57:[suppl 1]:3-6.
- (137) Harvey AT, Preskorn SH. Cytochrome P450 Enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. *J Clin Psychopharm* 1996; 16(4):273-285.
- (138) Harvey AT, Preskorn SH. Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. *J Clin Psychopharm* 1996; 16(5):345-355.
- (139) Walczak D, Apter JT, Halikas JA, Borison RL, Carman JS, Post GL et al. The oral dose-effect relationship for fluvoxamine: A fixed-dose comparison against placebo in depressed outpatients. *Ann Clin Psychiatr* 1996; 8(3):139-151.
- (140) Preskorn SH. Selection of an antidepressant: Mirtazapine. *J Clin Psychiatry* 1997; 58[suppl 6]:3-8.
- (141) Preskorn SH. Foreward. *J Clin Pharmacokinetics* 1997; 32(1):1.
- (142) Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. *Clin Pharmacokinet* 1997; 32[suppl 1]:1-21.
- (143) Tremaine L, Wilner K, Preskorn SH. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. *Clin Pharmacokinet* 1997; 32[suppl 1]:31-36.
- (144) Gardner MJ, Baris BA, Wilner KD, Preskorn SH. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. *Clin Pharmacokinet* 1997; 32(1):43-49.
- (145) Preskorn SH, Alderman J, Greenblatt DJ, Horst WD. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. *Psychopharmacol Bull* 1997; 33(4):659-665.
- (146) Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. *J Clin Psychopharmacol* 1997; 17(4):284-291.

- (147) Preskorn SH. Pharmacotherapeutic profile of venlafaxine. *Eur Psychiatry* 1997; 12[suppl 4]:285S-294S.
- (148) Preskorn SH, Harvey AT, Stanga C. Drug interactions and their role in patient care. *Current Review of Mood & Anxiety Disorders* 1997; 1:203-214.
- (149) Bhatara VS, Magnus RD, Paul KL, Preskorn SH. Serotonin syndrome induced by venlafaxine and fluoxetine: A case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. *Ann Pharmacother* 1998; 32:432-436.
- (150) Preskorn SH, Catterson M. Antidepressants and the elderly: Focus on newer agents. *International Journal of Geriatric Psychopharmacology* 1998; 1:66-77.
- (151) Preskorn SH. Debate resolved: There are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. *Journal of Psychopharmacology* 1998; 12(3) [suppl B]:S89-S97.
- (152) Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: Venlafaxine, nefazodone, bupropion. *J Affect Disord* 1998; 51:237-254.
- (153) Horst WD, Preskorn SH. The pharmacology and mode of action of venlafaxine. *Rev Contemp Pharmacother* 1998; 9:293-302.
- (154) Preskorn SH. Antidepressant options in primary care. *Clinical Cornerstone* 1999; 1(4):31-54.
- (155) Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants: Cost implications and relevance to clinical practice. *Clin Pharmacokinet* 1999; 37(2):147-165.
- (156) Catterson ML, Martin RL, Preskorn SH. Psychopharmacological drug-drug interactions in the elderly. *Clinical Geriatrics* 1999; 7(9):46-54.
- (157) Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. *Arch Gen Psychiatry* 2000; 57(5):503-509.
- (158) Findling RL, Preskorn SH, Marcus RN, Magnus RD, D'Amico F, Marathe P et al. Nefazodone pharmacokinetics in depressed children and adolescents. *J Am Acad Child Adolesc Psychiatry* 2000; 39(8):1008-1016.
- (159) Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. *J Clin Psychopharmacol* 2001; 21(2):161-166.
- (160) Shad M, Marsh C, Preskorn SH. The economic consequences of a drug-drug interaction. *J Clin Psychopharmacol* 2001; 21(1):119-120.
- (161) Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J et al. Efficacy and safety in mirtazapine in depressed patients after SSRI treatment failure: An open-label trial. *J Clin Psychiatry* 2001; 62(6):413-420.
- (162) Werder SF, Preskorn SH. Managing polypharmacy Walking the fine line. *Curr Psychiatr* 2003; 2(2):24-36.
- (163) Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild A, Snavely D et al. Demonstration of the efficacy and safety of a novel substance P(NK1) receptor antagonist (SPA) in major depression. *Neuropsychopharmacology* 2004; 29(2):385-392.
- (164) Preskorn SH, Flockhart DA. 2004 Guide to psychiatric drug interactions. *Primary Psychiatry* 2004; 11(2):39-60.
- (165) Preskorn SH. How drug-drug interactions can impact managed care. *Am J Manag Care* 2004; 10(6):S186-S198.
- (166) Preskorn SH. Why patients may not respond to usual recommended dosages. *Curr Psychiatry* 2004; 3(8):38-43.
- (167) Harvey AT, Flockhart DA, Gorski JC, Greenblatt DJ, Burke M, Werder SF et al. Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. *J Clin Pharmacol* 2004; 44:1173-1184.
- (168) Reyes JF, Preskorn SH, Khan AY, Kumar D, Cullen EI, Perdomo CA et al. Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: Assessment of pharmacokinetic changes and safety following multiple oral doses. *Brit J Clin Pharmacology* 2004; 58(1):50-57.
- (169) Khan AY, Preskorn SH, D'Empaire I. Something in the air. *Curr Psychiatr* 2004; 3(12):79-88.

- (170) Ramadan MI, Khan AY, Preskorn SH. D2-Blockade and possible ziprasidone-induced galactorrhea. *J Clin Psychopharm* 2005; 20(2):113-114.
- (171) Preskorn SH, Silkey B, Shah R, Neff M, Jones TL, Choi J et al. Complexity of medication use in the veterans affairs healthcare system: Part I: Outpatient use in relation to age and number of prescribers. *J Psychiatr Pract* 2005; 11(1):5-15.
- (172) Silkey B, Preskorn SH, Shah R. Complexity of medication use in the Veterans Affairs Healthcare System: Part II. Antidepressant use among younger and older outpatients. *J Psychiatr Pract* 2005; 11(1):16-26.
- (173) Khan AY, Preskorn SH. Examining concentration-dependent toxicity of clozapine: Role of therapeutic drug monitoring. *J Psychiatr Pract* 2005; 11(5):1-13.
- (174) Khan AY, Preskorn SH, Baker B. Effect of study criteria on recruitment and generalizability of the results. *J Clin Psychopharmacol* 2005 Jun;25(3):271-5.
- (175) Ahsan AY, Carrithers J, Preskorn SH, Wisniewski SR, Lear R, Rush AJ et al. Clinical and demographic factors associated with DSM-IV melancholic depression. *Ann Clin Psychiatr.* 2006;18(2): 91-99.
- (176) Preskorn SH. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. *Clin Pharmacokinet* 2006; 44(11):1117- 33.
- (177) Preskorn, S. H. and D. A. Flockhart. 2006 Guide to Psychiatric Drug Interactions. *Primary Psychiatry* 2006; 13(4): 35-64.
- (178) Preskorn, S.H. Pharmacogenomics, Informatics, and Individual Drug Therapy in Psychiatry: Past, Present and Future. *Psychopharmacology* 2006. 20:85-94.
- (179) Preskorn, S. and S. Werder, Detrimental antidepressant drug-drug interactions: Are they clinically relevant. *Neuropsychopharmacology*, 2006. 31:1605-1612.
- (180) Preskorn SH, Shah R, Neff M, Golbeck A, Choi J. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: Effects with fluoxetine and paroxetine versus sertraline. *J Psychiatr Pract* 2007; 13(1):5-12.
- (181) Preskorn SH, Greenblatt DJ, Flockhart DA, Luo Y, Perloff ES, Harmatz JS et al. Comparison of duloxetine, escitalopram and sertraline effects on cytochrome P450 (CYP) 2D6 function in healthy volunteers. *J Clin Psychopharmacol* 2007. 27(1):28-34.
- (182) Ozdemir V, Williams-Jones B, Graham JE, et al. Asymmetry in scientific method and limits to cross-disciplinary dialogue: Towards a shared language and science policy in pharmacogenomics and human disease genetics. *J Investig Med.* April 2007. 55(3):130-141.
- (183) Preskorn, S.H. A Precautionary Tale in Psychiatry. *Psych Times* 2007; 24:27-30.
- (184) Cascade,E.F., Kalali,A.H., and Preskorn,S.H. EMSAM: The First Year. *Psychiatry* 2007; 4:19-21.
- (185) Khan, A.Y., Preskorn, S.H., and Horst, W.D. Coadministration of Nefazodone and Desipramine: a pharmacokinetic interaction study. *Journal of Pakistan Medical Association* 2007; 57:230-235
- (186) Weiden, P.J., Preskorn, S.H., Fahnestock, P.A., Carpenter, D., Ross, R., and Docherty, J.P. Translating the Psychopharmacology of Antipsychotics to Individualized Treatment for Severe Mental Illness: A Roadmap. *J Clin Psychiatry* 2007;68 (Suppl 7) :1-48.
- (187) Preskorn, S. H., Lacey, R.L. Polypharmacy: When is it rational? *J Psychiatr Pract* 2007; 13: 97-105.
- (188) Lincoln, T., Preskorn, S. Out of the Pipeline: Desvenlafaxine *Current Psychiatry* 2008; 7(6): 89-96.
- (189) Preskorn, S. The Development and Use of Modern Psychotherapeutic Medications. *Psychiatric Times* 2008; 15:1.
- (190) Preskorn, S.H., Baker, et al. "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder." *J Clin Psychopharmacol* 2008; 28(6): 631-7. PMID 19011431

- (191) Lincoln, J., Preskorn, SH. Polydrug regimen: When it becomes irrational and how to simplify it in systematic manner. *Current Psychiatry* 2008; In Press.
- (192) Preskorn, S.H., Nichols, A., Paul, J., Patroneva, A., Helzner, E., Guico-Pabia, C. Effect of Desvenlafaxine on the Cytochrome P450 2D6 Enzyme System. *J Psychiatr Pract.* 2008; 14(6): 368-378.
- (193) Gandelman, K., Alderman, J., Glue, P., Lombardo, I., LaBadie, R.R., Versavel, M., Preskorn, S.H. The Impact of Calories and Fat Content of Meals on Oral Ziprasidone Absorption. *J Clin Psychiatry.* 2009; 70(1):58-62.
- (194) Preskorn, S.H., Patroneva, A., Silman, H., Pederson, R., Isler, J.A., Burczynski, M., Ahmed, S., Paul, J., Nichols, A.I., A Comparison of the Pharmacokinetics of Venlafaxine Extended Release and Desvenlafaxine Succinate in Extensive and Poor Cytochrome P450 2D6 Metabolizers. *J Clin Psychopharmacol* 2009; 29 (1): 39-43.
- (195) Warden D, Rush AJ, Wisniewski SR, Lesser IM, Kornstein SG, Balasubramain GK, Thase ME, Preskorn SH, et al., What predicts attrition in second step medication treatments for depression?: a STAR*D Report. *Int J Neuropsychopharmacol*, 2009. 12(4): p. 459-73
- (196) Preskorn SH. A roadmap to key pharmacologic principles in using antipsychotics: application in clinical practice [Academic Highlights]. *J Clin Psychiatry.* 2009; 70(4):593-600
- (197) Nichols AI, Lobello K, Guico-Pabia CJ, Paul J, Preskorn SH. Venlafaxine Metabolism as a Marker of Cytochrome P450 Enzyme 2D6 Metabolizer Status. *J Clin Psychopharmacol* 2009;29:383-386
- (198) Ereshefsky L, Culpepper L, Preskorn SH. The Use of Pharmacotherapy for Depression: The Importance of Drug-Drug Interactions. *Cli Symposia* 2009;59(1)
- (199) Chapel S, Hutmacher MM, Haig G, Bockbrader H, de Greef R, Preskorn SH, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. *J Clin Pharmacol.* 2009;49:1297-1308.
- (200) Preskorn SH, Flockhart D. 2010 Guide to Psychiatric Drug Interactions, *Primary Psychiatry.* 2009;16(12):45-74
- (201) Shelton RC, Hollon SD, Wisniewski SR, et al. Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D Report. *CNS Spectr* 2009;14(9):487-98 PMID 19890231
- (202) Khan A, Catterson ML, Preskorn S. Double-Blind Crossover Study of Mirtazapine, Amitriptyline and Placebo in Patients with Major Depressive Disorder. *Directions in Psychiatry* 2009;29(29(SR1)):125-30
- (203) Lincoln J, Preskorn S. Asenapine for schizophrenia and bipolar I disorder. *Curr Psychiatry* 2009;8(12):75-85
- (204) Chen ML, Shah VP, Ganes D, et al. Challenges and Opportunities in Establishing Scientific and Regulatory Standards for Assuring Therapeutic Equivalence of Modified Release Products: Workshop Summary Report. *Eur J Pharm Sci* 2010; 40(2):148-153 Epub 2010 March 27.
- (205) Chen ML, Shah VP, Ganes D, Midha KK, Caro J, Nambiar P, Rocci ML Jr, Thombre AG, Abrahamsson B, Conner D, Davit B, Fackler P, Farrell C, Gupta S, Katz R, Mehta M, Preskorn SH, et al. Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified release products: workshop summary report. *AAPS J.* 2010 Sep; 12(3):371-7. Epub 2010 May 4. PMID: 20440588
- (206) Chen ML, Shah VP, Ganes D, Midha KK, Caro J, Nambiar P, Rocci ML Jr, Thombre AG, Abrahamsson B, Conner D, Davit B, Fackler P, Farrell C, Gupta S, Katz R, Mehta M, Preskorn SH, et al. Challenges and opportunities in establishing scientific and regulatory standards for determining therapeutic equivalence of modified-release products: Workshop summary report. *Clin Ther.* 2010 Sep; 32(10):1704-12. PMID: 21194592
- (207) Lincoln J, Stewart M, Preskorn S. How Sequential Studies Inform Drug Development: Evaluating the Effect of Food Intake on Optimal Bioavailability of Ziprasidone. *J Psych Prac* 2010;16(2):103-14.
- (208) Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, Patroneva A, Ninan PT. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. *J Clin Psychiatry.* 2010; 71(11):1482-7. Epub 2010 Apr 6. PMID: 20441720

- (209) Macaluso M, Zackula R, D'Empaire I, Baker B, Liow K, Preskorn SH: Twenty percent of a representative sample of patients taking bupropion have abnormal, asymptomatic electroencephalographic findings. *J Clin Psychopharmacol*. 2010 Jun;30(3):312-7.
- (210) Macaluso M, Preskorn SH. CYP 2D6 PM status and antidepressant response to nortriptyline and venlafaxine: is it more than just drug metabolism? *J Clin Psychopharmacol*. 2011 Apr; 31(2):143-5. PMID: 21346604
- (211) Nichols AI, Focht K, Jiang Q, Preskorn SH, Kane CP. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. *Clin Drug Investig*. 2011; 31(3):155-67. PMID: 21288052
- (212) Daly EJ, Trivedi MH, Fava M, Shelton R, Wisniewski SR, Morris DW, Stegman D, Preskorn SH, Rush AJ. The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study. *J Clin Psychopharmacol*. 2011 Feb; 31(1):31-8. PMID: 21192140
- (213) Kalia R, Mittal, M, Preskorn SH. Vilazodone for major depressive disorder. *Current Psychiatry*. 2011; 10 (4):84-88.
- (214) Shen J, Preskorn S, Dragalin V, Slomkowski M, Padmanabhan SK, Fardipour P, Sharma A, Krams M: How Adaptive Trial Designs can Increase Efficiency in Psychiatric Drug Development: A Case Study. *Innov Clin Neurosci*. 2011 Jul;8(7):26-34.
- (215) D'Empaire I, Guico-Pabia CJ, Preskorn SH. Antidepressant treatment and altered CYP2D6 activity: Are pharmacokinetic variations clinically relevant? *J Psychiatr Pract*. 2011 Sep;17(5):330-9.
- (216) Savitz J, Preskorn S, Teague TK, Drevets D, Yates W, Drevets W: Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, doubleblind, placebo-controlled, 2x2 clinical trial. *BMJ Open* 2012; 2:e000643. (<http://dx.doi.org/10.1136/bmjopen-2011-000643>).
- (217) Preskorn S: Ketamine: The hopes and the hurdles. *Biol. Psychiatry* 2012; 522-23
- (218) Preskorn S: Changes in the Product Label for Pimozide: Both the Promises and the Challenges of Personalized Medicine. *J Clin Psychiatry* 2012; 73: 1191-1193.
- (219) Potkin S, Preskorn S, Hochfeld M, Meng X: "Thorough QTc study of iloperidone at three different dose with and without CYP 2D6 and/or 3A4 inhibition in comparison to quetiapine and ziprasidone. *J Clin Psychopharm* 2013; 33(1): 3-10
- (220) Preskorn S, Chiu Y, Poola N, Severs J, Sarubbi D, Loebel A, Ereshefsky L: Effects of food and meal composition on the pharmacokinetics of lurasidone, a novel atypical antipsychotic agent. *Hum Psychopharmacol*. 2013 Sep;28(5):495-505. doi: 10.1002/hup.2338.
- (221) Sung SC, Wisniewski SR, Balasubramani GK, Zisook S, Kurian B, Warden D, Trivedi MH, Rush AJ; CO-MED Study Team: Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. *Psychol Med*. 2013; 43(5):945-60. [Epub 2012 Dec 11.] (PMID: 23228340)
- (222) Preskorn S, Kane C, Lobello K, Nichols A, Fayyad R, Buckley G, Focht K, Guico-Pabia C: Cytochrome P₄₅₀ 2D6 phenocopy is common in patients being treated for depression: Implications for personalized medicine. *J Clin Psychiatry* 2013; 74 (6): 614 - 621 [published on-line ahead of print March 13, 2013 (doi:10.4088/JCP.12m07807)].
- (223) Preskorn S, Gawryl M, Dgetluck N, Palfreyman M, Bauer L, Hilt D: EVP-6124, an Alpha-7 Nicotinic Partial Agonist, Has Normalizing Effects on Event Related Potentials and Cognition: Randomized Trial in Patients with Schizophrenia. *J. Psychiatric Practice* 2014;20:12–24. (PMID: 24419307)
- (224) Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A: Lurasidone drug-drug interaction studies: a comprehensive review. *Drug Metabol Drug Interact*. 2014; 29(3):191-202. (PMID: 24825095)

- (225) Alexander RC, Preskorn S: Clinical pharmacology in the development of new antidepressants: the challenges. *Curr Opin Pharmacol.* 2014;14:6-10. [Epub 2013 Oct 19] (PMID: 24565005)
- (226) Preskorn SH: Prediction of individual response to antidepressants and antipsychotics: an integrated concept. *Dialogues Clin Neurosci.* 2014; 16(4):545-54. (PMID:25733958)
- (227) Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM: GLYX-13 Clinical Study Group. Randomized Proof of Concept Trial of GLYX-13, an N-Methyl-D-Aspartate Receptor Glycine Site Partial Agonist, in Major Depressive Disorder Nonresponsive to a Previous Antidepressant Agent. *J Psychiatr Pract.* 2015; 21(2):140-9. (PMID: 25782764)
- (228) Macaluso M, Nichols A, Preskorn SH. How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine As An Example. *Prim Care Companion CNS Disor* 2015;17(0):doi:10.4088/PCC.14r0171 PMID: 26445693
- (229) Preskorn S, Macaluso M, Trivedi M: How commonly used inclusion and exclusion criteria in antidepressant registration trials affect study enrollment. *J. Psychiatr. Pract.* 2015 July; 21(4) :267-74. doi: 10.1097/PRA.0000000000000082. PMID: 26164052
- (230) Macaluso M, Kazanchi H, Preskorn SH: How the pharmacokinetics and receptor-binding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia. *Expert Opin Drug Metab Toxicol.* 2015;11(8):1317-27. PMID: 26173973
- (231) Young KD, Drevets WC, Bodurka J, Preskorn SH: Amygdala activity during autobiographical memory recall as a biomarker for residual symptoms in patients remitted from depression. *Psychiatry Res.* 2016 Feb 28;248:159-61. doi: 10.1016/j.psychres.2016.01.017. Epub 2016 Jan 18. PMID: 26809279
- (232) Wehler CA, Preskorn SH: High false-positive rate of a putative biomarker test to aid in the diagnosis of schizophrenia. *J Clin Psychiatry.* 2016 Apr;77(4):e451-6. PMID: 27137429
- (233) Preskorn SH: Personalized Medicine in Psychiatry: Concepts for Bringing Associated Testing Into Clinical Practice. *Mayo Clin Proc.* 2016 Jul;91(7):827-9. PMID: 27289412
- (234) Young KD, Preskorn SH, Victor T, Misaki M, Bodurka J, Drevets WC: The Effect of Mineralocorticoid and Glucocorticoid Receptor Antagonism on Autobiographical Memory Recall and Amygdala Response to Implicit Emotional Stimuli. *Int J Neuropsychopharmacol.* 2016 Sep 21;19(9). PMID: 27207909
- (235) Savitz JB, Teague TK, Misaki M, Macaluso M, Wurfel BE, Meyer M, Drevets D, Yates W, Gleason O, Drevets WC, Preskorn SH: Treatment of Bipolar Depression with Minocycline and/or Aspirin: An adaptive, 2 X 2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. *Translational Psychiatry*, in press.
- (236) Brittain CF, Gray FA, Alexander RC, Bettica P, Preskorn SH: Adverse Events: A new method to quantify the rate and severity of adverse events during drug development to assess for differences in tolerability between healthy volunteers and specific patient populations. Submitted to *Journal of Clinical Psychopharmacology*
- (237) Alexander R, Gray F, Bettica P, Preskorn S: A bridging study of the pan 5-HT₁ autoreceptor antagonist GSK163090 in patients with major depression. Submitted.
- (238) Bettica P, Alexander R, Gray F, Preskorn S: Safety, tolerability and 5-HT₁ receptor occupancy achieved with different doses of GSK163090, a pan 5-HT₁ autoreceptor antagonist, in healthy volunteers. In development.
- (239) Valuck R, Libby A, Anderson H, Bagley C, Luetters A, Erder M, Francois C, Doshi J, Collins C, Preskorn S: Rates of Co-Prescribing of Drugs with Potential for Drug-Drug Interactions among Persons Initiating Therapy with Selective Serotonin Reuptake Inhibitors. In preparation.
- (240) Valuck R, Libby A, Anderson H, Bagley C, Luetters A, Erder M, Milea D, Doshi J, Collins C, Preskorn S: Likelihood of Potential Drug-Drug Interactions among Persons Initiating Therapy with Selective Serotonin Reuptake Inhibitors. In preparation.

Columns:

- (1) Preskorn SH. Psychiatry: Into the 21st century. *J Prac Psych and Behav Hlth* 1995; 1(2):130-131.
- (2) Preskorn SH. Advances in psychiatry through genes, molecules and images. *J Prac Psych and Behav Hlth* 1995; 1(3):193-195.
- (3) Preskorn SH. What is the message in the alphabet soup of cytochrome P450 enzymes? *J Prac Psych and Behav Hlth* 1995; 1:237-240.
- (4) Preskorn SH. Why did Terry fall off the dose-response curve? *J Prac Psych and Behav Hlth* 1996; 2(1):39-43.
- (5) Preskorn SH. Have you phenotyped your patient lately? *J Prac Psych and Behav Hlth* 1996; 2(2):115-117.
- (6) Preskorn SH. To monitor or not to monitor? *J Prac Psych and Behav Hlth* 1996; 2(3):172-175.
- (7) Preskorn SH. A dangerous idea. *J Prac Psych and Behav Hlth* 1996; 2(4):231-234.
- (8) Preskorn SH. To monitor or not to monitor, II: The glass is more than half full. *J Prac Psych and Behav Hlth* 1996; 2(5):307-310.
- (9) Preskorn SH. If lack of concentration didn't cause the fall, what did? *J Prac Psych and Behav Hlth* 1996; 2(6):364-367.
- (10) Preskorn SH. Let the data speak to you. *J Prac Psych and Behav Hlth* 1997; 3(1):45-48.
- (11) Preskorn SH. Do you believe in magic? *J Prac Psych and Behav Hlth* 1997; 3(2):99-103.
- (12) Preskorn SH. Patients don't fail treatments, treatments fail patients. *J Prac Psych and Behav Hlth* 1997; 3(3):165-168.
- (13) Preskorn SH. The appearance of knowledge. *J Prac Psych and Behav Hlth* 1997; 3(4):233-238.
- (14) Preskorn SH. I don't see 'em. *J Prac Psych and Behav Hlth* 1997; 3(5):302-307.
- (15) Preskorn SH. Pandora's box: Pregnancy and antidepressants. *J Prac Psych and Behav Hlth* 1997; 3(6):363-365.
- (16) Preskorn SH. Do you feel lucky? *J Prac Psych and Behav Hlth* 1998; 4(1):37-40.
- (17) Preskorn SH. Marooned: Only one choice. *J Prac Psych and Behav Hlth* 1998; 4(2):110-114.
- (18) Preskorn SH. 11.2 billion dollars: Is it worth it? *J Prac Psych and Behav Hlth* 1998; 4(3):163-168.
- (19) Preskorn SH. A message from Titanic. *J Prac Psych and Behav Hlth* 1998; 4(4):236-242.
- (20) Preskorn SH. Sweetness. *J Prac Psych and Behav Hlth* 1998; 4(5):304-308.
- (21) Preskorn SH. What happened to Tommy? *J Prac Psych and Behav Hlth* 1998; 4(6):363-367.
- (22) Preskorn SH. The slippery slide. *J Prac Psych and Behav Hlth* 1999; 5(1):50-55.
- (23) Preskorn SH. Finding the signal through the noise: The use of surrogate markers. *J Prac Psych and Behav Hlth* 1999; 5(2):104-109.
- (24) Preskorn SH. A tale of two patients. *J Prac Psych and Behav Hlth* 1999; 5(3):160-164.
- (25) Preskorn SH. Defining "is". *J Prac Psych and Behav Hlth* 1999; 5(4):224-228.
- (26) Preskorn SH. De-spinning *in vitro* data. *J Prac Psych and Behav Hlth* 1999; 5(5):283-287.
- (27) Preskorn SH. Two in one: The venlafaxine story. *J Prac Psych and Behav Hlth* 1999; 5(6):346-350.
- (28) Preskorn SH. Bupropion: What mechanism of action? *J Prac Psych and Behav Hlth* 2000; 6(1):39-44.
- (29) Preskorn SH. Imipramine, mirtazapine, and nefazodone: Multiple targets. *J Prac Psych and Behav Hlth* 2000; 6(2):97-102.
- (30) Preskorn SH. The adverse effect of the selective serotonin reuptake inhibitors: Relationship to *in vitro* pharmacology. *J Psychiatr Pract* 2000; 6(3):218-223.

- (31) Preskorn SH. The relative adverse effect profile of non-SSRI antidepressants: Relationship to *in vitro* pharmacology. *J Psychiatr Pract* 2000; 6(4):218-223.
- (32) Preskorn SH. The human genome project and modern drug development in psychiatry. *J Psychiatr Pract* 2000; 6(5):272-276.
- (33) Preskorn SH. The stages of drug development and the human genome project: Drug discovery. *J Psychiatr Pract* 2000; 6(6):341-344.
- (34) Preskorn SH, Silkey B. Multiple medications, multiple considerations. *J Psychiatr Pract* 2001; 7(1):48-52.
- (35) Preskorn SH. The human genome project and drug discovery in psychiatry: Identifying novel targets. *J Psychiatr Pract* 2001; 7(2):133-140.
- (36) Preskorn SH. Antipsychotic drug development in the pre-human-genome era: A full circle. *J Psychiatr Pract* 2001; 7(3):209-213.
- (37) Preskorn SH. Drug discovery in psychiatry: Drilling down on the target of interest. *J Psychiatr Pract* 2001; 7(4):267-272.
- (38) Preskorn SH. Drug development in psychiatry and the human genome project: The explosion in knowledge and potential targets. *J Psychiatr Pract* 2001; 7(5):336-340.
- (39) Preskorn SH. Drug development in psychiatry and genomics: From E. coli to man. *J Psychiatr Pract* 2001; 7(6):415-419.
- (40) Preskorn SH. Drug approvals and withdrawals over the last 60 years. *J Psychiatr Pract* 2002; 7(8):41-50.
- (41) Preskorn SH, Silkey B, Jones TL. Physician perceptions of drug-drug interactions and how to avoid them. *J Psychiatr Pract* 2002; 8(2):112-115.
- (42) Preskorn SH, Baker B. The overlap of DSM-IV syndromes: Potential implications for the practice of polypharmacology, psychiatric drug development and the human genome project. *J Psychiatr Pract* 2002; 8(3):170-177.
- (43) Preskorn SH. Fatal drug-drug interactions as a differential consideration in apparent suicides. *J Psychiatr Pract* 2002; 8(4):233-238.
- (44) Preskorn SH. Clinical pharmacology case conference: A suicide attempt? *J Psychiatr Pract* 2002; 8(5):306-310.
- (45) Preskorn SH. Polypharmacy in a patient with refractory major depression: Part I: The case. *J Psychiatr Pract* 2002; 8(6):370-376.
- (46) Preskorn SH. Polypharmacy in a case of refractory major depression: Part II: Implications for clinical management. *J Psychiatr Pract* 2003; 9(1):71-78.
- (47) Preskorn SH. Reproducibility of the *in vivo* effect of the selective serotonin reuptake inhibitors on the *in vivo* function of cytochrome P450 2D6: An update (part I). *J Psychiatr Pract* 2003; 9(2):150-158.
- (48) Reproducibility of the *in vivo* effect of the selective serotonin reuptake inhibitors on the *in vivo* function of cytochrome P450 2D6: An update (part II). *J Psychiatr Pract* 2003; 9(3):228-236.
- (49) Preskorn SH. Relating clinical trials to Psychiatric Practice: Part I: The case of a 13-year old on Aripiprazole and fluoxetine. *J Psychiatr Pract* 2003; 9(4):307-313.
- (50) Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions. *J Psychiatr Pract* 3 A.D.; 10(3):177-181.
- (51) Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions (Part II). *J Psychiatr Pract* 2004;10(3):177-81.
- (52) Preskorn SH. Reboxetine: A selective norepinephrine reuptake pump inhibitor. *J Psychiatr Pract* 2004; 10(1):57-63.

- (53) Preskorn SH. Milnacipran: A dual norepinephrine and serotonin reuptake pump inhibitor. *J Psychiatr Pract* 2004; 10(2):119-126.
- (54) Preskorn SH. The recommended dose range: How is it established and why would it ever be exceeded. *J Psychiatr Pract* 2004; 10(4):249-254.
- (55) Preskorn SH. Tianeptine: A facilitator of the reuptake of serotonin and norepinephrine as an antidepressant. *J Psychiatr Pract* 2004; 10(5):323-330.
- (56) Preskorn SH. Duloxetine. *J Psychiatr Pract* 2004; 10(6):375-385.
- (57) Preskorn SH. Multiple medication Use in patients seen in the Veterans Affairs Healthcare System: So what? *J Psychiatr Pract* 2005; 11(1):46-50.
- (58) Preskorn SH. Drug-Drug interactions: Proof of relevance. *J Psychiatr Pract* 2005; 11(2):116-122.
- (59) Preskorn SH. Drug-Drug Interactions: Proof of relevance (Part II): Cause of tolerability problems or noncompliance. *J Psychiatr Pract* 2005;11(6):397-401.
- (60) Preskorn SH. The difference between the formal and the functional dose: The case of the patient of thioridazine and fluvoxamine. *J Psychiatr Pract* 2005; 11(3):192-196.
- (61) Preskorn SH. Clinical application of the concept of relative potency: An example involving chlorpromazine and haloperidol. *J Psychiatr Pract* 2005; 11(4):258-261.
- (62) Preskorn SH. Comments on the role of therapeutic drug monitoring for clozapine. *J Psych Pract* 2005; 11(5):340-343.
- (63) Preskorn SH. Psychopharmacology and psychotherapy: what's the connection. *J Psychiatr Pract* 2006; 12(1):41-45.
- (64) Preskorn SH. Patient with bipolar disorder and familial QT prolongation: What to do? *J Psychiatr Pract* 2006;12(2):109-12.
- (65) Preskorn SH. Why the transdermal delivery of selegiline obviates the need for a dietary restriction on tyramine. *J Psychiatr Pract* 2006;12(3):168-72.
- (66) Preskorn SH. Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part I. *J Psychiatr Pract* 2006;12(4):244-9.
- (67) Preskorn SH, Borges-Gonzalez S, Flockhart DA. Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II. *J Psychiatr Pract* 2006; 12(5):312-316.
- (68) Preskorn SH. Drugs are an acquired source of biological variance among patients. *J Psychiatr Pract* 2006; 12(6):391-396.
- (69) Preskorn, SH. Mania in a Case of Polypharmacology: Pharmacodynamic and Pharmacokinetic Considerations - Do You Believe in Magic? *J Psychiatr Pract* 2007, **13**:178-183.
- (70) Preskorn, SH. The Evolution of Antipsychotic Drug Therapy: Reserpine, Chlorpromazine, and Haloperidol. *J Psychiatr Pract* 2007, **13**:253-257.
- (71) Preskorn, S., Clinical relevance of relative receptor binding affinity: Quetiapine and ziprasidone as examples. *J Psychiatr Pract*. 2007. 13(6): p.393-398.
- (72) Preskorn, S. H. Neuroleptic Malignant Syndrome Resulting From a Complex Drug-Drug Interaction: "I Don't See 'Em!" *J Psychiatr Pract*.2007, 13(5): 328-333.
- (73) Preskorn, SH. Flat dose-response curves for efficacy: what do they mean to the clinician? *J Psychiatr Pract* 2008, 14(4): 232-6.
- (74) Preskorn, SH. Multiple Medication Use Presenting as Parkinson's Dementia Complex: A Message from Titanic. *J Psychiatr Pract* 2008, 14(1): 45-54.
- (75) Preskorn, SH. Deconstructing a medication regimen. *J Psychiatr Pract* 2008, **14**(2): 114-8.

- (76) Preskorn, SH. How multiple medication use evolves and the importance of therapeutic trials: the slippery slide. *J Psychiatr Pract* 2008, **14**(3): 170-5.
- (77) Preskorn, SH. Practical Application of Therapeutic Drug Monitoring: A Tale of Two Patients. *J Psychiatr Pract* 2008, **14**(5): 301-306.
- (78) Preskorn, SH. Results of the STAR*D Study: Implications for Clinicians and Drug Developers. *J Psychiatr Pract* 2009, **15**(1): 45-49. PMID 19182564
- (79) Preskorn SH. Patients who do not respond to the "usual" dose: why Terry fell off the dose-response curve. *J Psychiatr Pract* 2009;15(6):460-6
- (80) Preskorn, SH., Drevets, WC. Neuroscience Basis of Clinical Depression: Implications for Future Antidepressant Drug Development. *J Psychiatr Pract* 2009, **15**(2): 125-132
- (81) Preskorn, SH. Treatment Options for the Patient Who Does Not Respond Well to Initial Antidepressant Therapy. *J Psychiatr Pract* 2009, **15**(3): 202-210.
- (82) Preskorn, SH. How and Why Study Designs Affect the Nature and Validity of Study Results: Appearance Versus True Knowledge. Part 1. *J Psychiatr Pract* 2009, **15**(4): 306-310.
- (83) Preskorn, S.H. How and why study designs affect the nature and validity of study results: appearance versus true knowledge. Part II. *J Psychiatr Pract*, 2009. 15(5): p. 402-7.
- (84) Preskorn, SH. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters. *J Psychiatr Pract*, 2010;16(1):46-9.
- (85) Preskorn, SH. Outliers on the Dose-Response Curve: How to Minimize This Problem Using Therapeutic Drug Monitoring, an Underutilized Tool in Psychiatry. *J Psychiatric Practice* 2010;16 (3):177–182.
- (86) Preskorn, SH. CNS drug development. Part I: The early period of CNS drugs. *J Psychiatr Pract*. 2010; 16(5):334-9. PMID: 20859110
- (87) Preskorn, SH. CNS drug development: Part II: Advances from the 1960s to the 1990s. *J Psychiatr Pract*. 2010; 16(6):413-5. PMID: 21107146
- (88) Preskorn, SH. CNS drug development: part III: future directions. *J Psychiatr Pract*. 2011; 17(1):49-52. PMID: 21266894
- (89) Preskorn S: Inadvertent Fatal Imipramine Poisoning of a Child: What Happened to Tommy? *J Psychiatric Practice* 2011;17(2): 118–123
- (90) Macaluso M, Krams M, Preskorn SH. Phase I Trials: From Traditional to Newer Approaches. Part I. *J Psychiatric Practice*. 2011; 17(3):200-203. PMID: 21586998
- (91) Macaluso M, Krams M, Preskorn SH. Phase I Trials: From Traditional to Newer Approaches. Part II. *J Psychiatric Practice* 2011; 17(4):277-284. PMID: 21775829
- (92) Preskorn S: What Do the Terms “Drug-Specific Response/Remission Rate” and “Placebo” Really Mean? *J Psychiatric Practice* 2011; 17(6):420–424.
- (93) Preskorn S: The Use of Biomarkers in Psychiatric Research: How Serotonin Transporter Occupancy Explains the Dose-Response Curves of SSRIs. *J Psychiatric Practice* 2012; 18 (1):38-45.
- (94) Macaluso M, Preskorn S: How Biomarkers Will Change Psychiatry: From Clinical Trials to Practice. Part I: Introduction *J Psychiatric Practice* 2012; 18 (2): 118-121.
- (95) Preskorn S: Clinically Important Differences in the Pharmacokinetics of the Ten Newer “Atypical” Antipsychotics: Part 1. *J Psychiatric Practice* 2012; 18 (2): 199-204.
- (96) Macaluso M, Drevets W, Preskorn S: How Biomarkers Will Change Psychiatry Part II: Biomarker Selection and Potential Inflammatory Markers of Depression. *J Psychiatric Practice* 2012; 18 (2): 281-286.

- (97) Preskorn S: Clinically Important Differences in the Pharmacokinetics of the Ten Newer “Atypical” Antipsychotics: Part 2. Metabolism and Elimination. *J Psychiatric Practice* 2012; 18 (2): 361-368.
- (98) Preskorn S: Clinically Important Differences in the Pharmacokinetics of the Ten Newer “Atypical” Antipsychotics: Part 3. Effects of Renal and Hepatic Impairment. *Journal of Psychiatric Practice* 2012;18:430–437
- (99) Preskorn SH, Khan A: Rationality of multiple medication use in medicine generally and psychiatry specifically: A dimensional perspective. *Journal of Psychiatric Practice* 2013; 19(1): 54-61.
- (100) Preskorn SH, Hatt C: How Pharmacogenomics (PG) Are Changing Practice: Implications for Prescribers, Their Patients, and the Healthcare System (PG Series Part I). *Journal of Psychiatric Practice* 2013;19: 142–149
- (101) Preskorn S: Declining Differences in Response Rates with Antidepressants versus Placebo: A Modest Proposal for Another Contributing Cause. *Journal of Psychiatric Practice* 2013;19: 227–233
- (102) Young K, Preskorn S: Neuroscientific Basis of Corticosteroid-Induced Changes in Human Cognitive and Emotional Processing: Implications for Affective Illness. *Journal of Psychiatric Practice* 2013; 19: 309 -315.
- (103) Preskorn S: Complexities of Personalized Medicine: How Genes, Drug-Drug Interactions, Dosing Schedules, and Other Factors Can Combine to Produce Clinically Meaningful Differences in a Drug’s Effect. *Journal of Psychiatric Practice* 2013; 19:397–405.
- (104) Preskorn SH: Outliers on the dose-response curve: if the problem is not concentration, then what? *J Psychiatric Practice* 2013; 19(6):490-4. (PMID: 24241502)
- (105) Preskorn SH: Therapeutic Drug Monitoring (TDM) in psychiatry (part I): why studies attempting to correlate drug concentration and antidepressant response don't work. *J Psychiatric Practice* 2014; 20(2):133-7. (PMID: 24638047)
- (106) Preskorn SH: The role of proof of concept (POC) studies in drug development using the EVP-6124 POC study as an example. *J Psychiatric Practice* 2014; 20(1):59-60. (PMID: 24419310)
- (107) Preskorn SH: Clinical psychopharmacology and medical malpractice: the four Ds. *J Psychiatric Practice* 2014; 20(5):363-8. (PMID: 25226197)
- (108) McMahon D, Preskorn SH: The package insert: who writes it and why, what are its implications, and how well does medical school explain it? *J Psychiatric Practice* 2014; 20(4):284-90. (PMID: 25036584)
- (109) Preskorn SH: CNS drug development: lessons from the development of ondansetron, aprepitant, ramelteon, varenicline, lorcaserin, and suvorexant. Part I. *J Psychiatric Practice* 2014; 20(6):460-5. (PMID: 25406050)
- (110) Preskorn SH: CNS drug development: lessons learned Part 2. Symptoms, not syndromes as targets consistent with the NIMH research domain approach. *J Psychiatric Practice* 2015; 21(1):60-6. (PMID: 25603452)
- (111) Preskorn SH, Flynn A, Macaluso M. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1. *Journal of Psychiatric Practice* 2015 September; 21(5). PMID: 26348804
- (112) Preskorn SH: A Way of Conceptualizing Benzodiazepines to Guide Clinical Use. *J Psychiatr Pract.* 2015 Nov;21(6):436-41. doi: 10.1097/PRA.000000000000114. PMID: 26554326
- (113) Macaluso M, Flynn A, Preskorn SH. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 2: Preclinical and Early Phase Human Proof of Concept Studies. *Journal of Psychiatric Practice.* 2016 January; 22(1). PMID: 26813487
- (114) Preskorn S, Macaluso M: Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data. *Journal of Psychiatric Practice* 2016; 22; 117 – 123.

- (115) Macaluso M, Flynn A, Preskorn S: Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data. *J Psychiatr Pract.* 2016 May;22(3):203-20. PMID: 27123800
- (116) Preskorn SH: New Laboratory Tests in Psychiatry: What Should Mental Health Practitioners Know? *J Psychiatr Pract.* 2016 Jul;22(4):308-12. PMID: 27427842
- (117) Preskorn SH: Use of an Analog Scale in the Treatment of Patients With Major Depressive Disorder to Optimize Assessment and Clinical Outcome. *J Psychiatr Pract.* 2016 Nov;22(6):463-466. PMID: 27824779
- (118) Preskorn SH: National Initiative to Prevent Suicide (NIPS): A New Proposal to Improve the Understanding and Prevention of Suicide. *J Psychiatr Pract.* 2016 Sep;22(5):398-404. PMID: 27648504
- (119) Preskorn SH: Use of an Analog Scale in the Treatment of Patients With Bipolar Disorder to Optimize Assessment and Clinical Outcome. *J Psychiatr Pract.* 2017 Jan;23(1):44-48. PMID: 28072644
- (120) Macaluso M, Flynn A, Preskorn SH: Tardive Dyskinesia: A Historical Perspective. *J Psychiatr Pract.* 2017 Mar;23(2):121-129. doi: 10.1097 PMID: 28291037
- (121) Preskorn S: Switching From the Oral to the Depot Formulation of a Medication: Clinically Relevant Pharmacokinetic Concepts and Considerations. *J. Psychiatr. Pract.* 2017; 23 (3):200-209
- (122) Preskorn S: Psychiatric and Central Nervous System Drugs Developed Over the Last Decade: What Are the Implications for the Field? *J. Psychiatr. Pract.* 2017; 23 (5):352– 360
- (123) Preskorn S. CNS Drug Development, Lessons Learned, Part 4: The Role of Brain Circuitry and Genes—Tasimelteon as an Example. *J. Psychiatr. Pract.* 2017;23 (6):425-430
- (124) Preskorn S: CNS Drug Development, Lessons Learned, Part 5: How Preclinical and Human Safety Studies Inform the Approval and Subsequent Use of a New Drug—Suvorexant as an Example. *J. Psychiatr. Pract.* 2018;24; in press.

Book Chapters

- (1) Hartman BK, Swanson LW, Raichle ME, Clark HB, Preskorn SH. Evidence for central adrenergic regulation of cerebral vascular permeability and blood flow. In: Usdin E, Kopin IJ, Barchas JD, editors. *Basic and clinical frontiers of catecholamine research.* New York: Pergamon Press, 1979: 450-453.
- (2) Hartman B, Preskorn SH, Raichle M, Swanson L, Clark B. The effect of tricyclic antidepressants on cerebral capillary permeability: An action on a fundamental cerebral homeostatic mechanism. In: Mendels J, editor. *Psychobiology of Affective Disorders.* Philadelphia: Karger, 1979: 25-48.
- (4) Hartman BK, Swanson LW, Raichle ME, Preskorn SH, Clark HB. Central adrenergic regulation of cerebral microvascular permeability and blood flow; anatomic and physiologic evidence. In: Eisenberg HM, Suddith RL, editors. *The Cerebral Microvasculature.* Unknown: Plenum Publishing Corporation, 1980: 113-126.
- (5) Preskorn SH, Hartman B. Cerebrovascular effects of antidepressants: basic and clinical implications. In: Usdin U, Eckert U, Forest U, editors. *Phenothiazines and Structurally Related Drugs: Basic and Clinical Studies.* Elsevier North Holland, Inc., 1980: 95-98.
- (6) Preskorn SH. Tardive dyskinesia and related neuroleptic-induced disorders. In: Helzer J, Martin R, Guze S, editors. *Milliken Series in Psychiatry.* St. Louis: Milliken, 1980.

- (7) Goodwin DW, Preskorn SH. Factors affecting the biphasic concentration: effect relationships of tricyclic antidepressants. In: Usdin E, Dahl SG, Gram LF, Lingjaerde O, editors. *Clinical Pharmacology in Psychiatry*. Macmillan Publishers LTD, 1981: 297-306.
- (8) Goodwin DW, Preskorn SH. DSM-III and pharmacotherapy. In: Turner S, Hersen M, editors. *Adult Psychopathology: A Social Work Perspective*. New York, NY: John Wiley & Sons, 1982: 453-465.
- (9) Preskorn SH. Clinical value of plasma monitoring of antidepressants. In: Ayd FJ, Jr., Taylor IJ, Taylor BT, editors. *Affective Disorders Reassessed: 1983*. Baltimore: Ayd Medical Communications, 1983: 100-114.
- (10) Preskorn SH. Plasma monitoring of antidepressants. In: Berner P, editor. *Proceedings of the VII World Congress of Psychiatry*. New York: Plenum Press, 1983.
- (11) Preskorn SH, Kent TA. Mechanisms and interventions in tricyclic antidepressant overdoses. In: Stancer HC, Garfinkel PE, Rakoff VM, editors. *Guidelines for the Use of Psychotropic Drugs*. New York: Spectrum Publications Inc., 1984: 63-75.
- (12) Hughes C, Preskorn SH, Adams R, Kent T. Etiology of schizophrenia and affective disorders: Neurobiological. In: Cavenar JO, editor. *Psychiatry*. Philadelphia: Lippincott, 1985: 1-16.
- (13) Hughes CW, Preskorn SH, Adams RN, Kent TA. Neurobiological etiology of schizophrenia and affective disorders (1998). In: Michels R, Cavenar JO, Bridie HK, Cooper AM, Guse SB, Judd LL et al., editors. *Psychiatry*. New York: J.B. Lippincott, 1988: 1-16.
- (14) Preskorn SH, Gold M, Extein I. Drug level monitoring in psychiatry. In: Gold MS, editor. *Diagnostic and Laboratory Testing in Psychiatry*. New York: Plenum Press, 1986: 131-154.
- (15) Preskorn SH. Childhood affective disorders. In: Buckalew J, editor. *National Depressive and Manic Depressive Association Educational Series*. Dallas: NDMDA, 1986.
- (16) Preskorn SH. Treatment of tricyclic-resistant depression: The role of tricyclic antidepressant plasma level monitoring. In: Extein IL, editor. *Role of Plasma Level Monitoring*. Washington D.C.: APA Press, 1989: 3-25.
- (17) Preskorn SH. Therapeutic drug monitoring of tricyclic antidepressants: a means of avoiding toxicity. In: Dahl S, Graham L, editors. *Clinical Pharmacology in Psychiatry: From Molecular Studies to Clinical Reality*. Heidelberg: Springer-Verlag, 1989: 237-243.
- (18) Preskorn SH, Weller E, Hughes C, Weller R. Depression in children: defining therapeutic range for imipramine. In: Lerer B, Gershon S, editors. *New Direction in Affective Disorders*. New York, NY: Springer-Verlag, 2000.
- (19) Preskorn SH. Antidepressant drug use in pediatric and adolescent patients with affective disorder. In: Amsterdam JD, editor. *Pharmacotherapy of depression*. New York: Marcel Dekker, Inc., 1996: 321-335.
- (20) Preskorn SH, Goodwin WG, Erickson H. DSM-III-R and pharmacotherapy. In: Hersen M, Turner S, editors. *Adult Psychopathology and Diagnosis*. New York: John Wiley and Sons, Inc., 1991: 482-499.
- (21) Preskorn SH, Hughes CW, Bupp SJ. Neurobiological etiology of schizophrenia and effective disorders (revised). In: Michell R, Cooper AM, Guze SB, Judd LL, Kierman GL, Solnit AJ et al., editors. *Psychiatry*. Philadelphia: Lippincott, 1992: 1-23.
- (22) Preskorn SH. Serotonin receptor subtypes and their implications for psychiatric disorders. Hagerman RJ, McKenzie P, editors. *International Fragile X Conference Proceedings*, 179-194. 1992. Dillon, CO., SPECTRA Publishing Co.
- (23) Fast GA, Preskorn SH. Therapeutic drug monitoring. In: Dunner DL, editor. *Current Psychiatric Therapy*. Philadelphia: W.B.Saunders, 1993: 529-534.
- (24) Preskorn SH. Dose-effect and concentration-effect relationships with new antidepressants. In: Gram LF, Balant LP, Meltz HY, Dahl SG, editors. *Clinical Pharmacology in Psychiatry*. Heidelberg: Springer-Verlag, 1993: 174-189.
- (25) Preskorn SH, Burke M, Fast GA. Therapeutic drug monitoring. *Principals and practice. Psychiatric Clinics of North America* 1993; 16(3):611-646.

- (26) Martin R, Preskorn SH. The use of the laboratory in psychiatry. In: Winokur G, Clayton PJ, editors. *Medical Basis of Psychiatry*. St. Louis, MO: W. B. Saunders Company, 1994: 493-509.
- (27) Burke M, Preskorn SH. Short-term treatment of mood disorders with standard antidepressants. In: Bloom FE, Kupfer D, editors. *Psychopharmacology: The Fourth Generation of Progress*. New York: Raven Press, 1995: 1053-1065.
- (28) Preskorn SH. Psychopharmacology. In: Simpson GM, editor. *Manual of Psychiatric Disorders*. New York: Impact Communications, 1995: 160-211.
- (29) Preskorn SH. The importance of pharmacodynamic and pharmacokinetic considerations in the selection of antidepressant therapy for the elderly. In: Vellas BJ, Albaredo L, Garry PJ, editors. *Mood and Cognitive Disorders (Facts and Research in Gerontology Journal, 1995 [suppl])*. New York, NY: Springer Publisher, 536 Broadway, 1995: 187-204.
- (30) Preskorn SH. Selection d'un traitement pharmacologique chez le sujet déprimé. In: Vellas P, Albaredo JL, Garry PJ, editors. *L'Année Gerontologique*. Paris: Serdi, 1995: 372-373.
- (31) Preskorn SH, Harvey AT, Stanga C. Drug interactions and their role in patient care. *Current Review of Mood & Anxiety Disorders* 1997; 1:203-214.
- (32) Horst W, Preskorn SH. Intracellular and intercellular principles of the pharmacotherapy of patients with neuropsychiatric disorders. In: Yudofsky S, Hales R, editors. *Neuropsychiatry*. Washington DC: American Psychiatric Press, Inc., 1997: 55-75.
- (33) Preskorn SH. Foreword. In: Knesper DJ, Riba MB, Schwenk TL, editors. *Primary Care Psychiatry*. Philadelphia: W.B. Saunders, 1997.
- (34) Catterson M, Preskorn SH, Martin R. Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. In: Martin R, editor. *Geriatric Psychiatry: What's New with the Old? In: The Psychiatric Clinics of North America*. Philadelphia: W.B. Saunders Co., 1997: 205-218.
- (35) Preskorn SH. Recent dose-effect studies regarding antidepressants. In: Balant LP, Benitez J, Dahl SG, Gram LF, Pinder RM, Potter WZ, editors. *European Cooperation in the Field of Scientific and Technical Research*. Belgium: European Commission, 1998: 45-61.
- (36) Preskorn SH, Harvey AT. Cytochrome P450 enzymes and psychopharmacology. In: Watson SJ, editor. *Fourth Generation of Progress*. 1998.
- (37) Shad MU, Preskorn SH. Antidepressants. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. *Metabolic Drug Interactions*. Philadelphia: Lippincott, Williams & Wilkins, 2000: 563-577.
- (38) Preskorn SH. Methodological issues in psychopharmacogenetics. In: Lerer B, editor. *Pharmacogenetics of Psychotropic Drugs*. NY: Cambridge University, 2002: 57.
- (39) Preskorn SH. Mood disorders method of. In: Rakel RE, Bope ET, editors. *Conn's Current Therapy*. Philadelphia: Saunders (Elsevier Science), 2003: 1196-1204.
- (40) Khan AY, Preskorn SH. Pharmacokinetic principles and drug interactions. *Handbook of medical psychiatry*. 2003: 945-944.
- (41) Preskorn SH, Catterson ML. General principles of pharmacokinetics. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. *Antidepressants: Past, present and future*. Heidelberg: Springer-Verlag, 2004: 35-86.
- (42) Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. *Antidepressants: Past, Present and Future*. Heidelberg: Springer-Verlag, 2004: 87-114.
- (43) Preskorn SH, Ross R. Overview of currently available antidepressants. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. *Antidepressants: Past, Present and Future*. Heidelberg: Springer-Verlag, 2004: 171-183.
- (44) Preskorn SH, Ross R, Stanga CY. Selective serotonin reuptake inhibitors. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. *Antidepressants: Past, Present and Future*. Heidelberg: Springer-Verlag, 2004: 241-262.

- (45) Preskorn SH, Ross R. Other antidepressants. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. *Antidepressants: Past, Present and Future*. Heidelberg: Springer-Verlag, 2004: 263-324.
- (46) Preskorn SH. Role of pharmacogenetics/pharmacogenomics in the development of new antidepressants. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. *Antidepressants: Past, Present and Future*. Heidelberg: Springer-Verlag, 2004: 583-607.
- (47) D'Empaire I, Preskorn SH. Use of Laboratory Assessments in Psychiatry. In: Fatemi SH, Clayton PJ, Editors, *The Medical Basis of Psychiatry..* Totowa, NJ: Humana Press. 2008; 535-546
- (48) Lincoln J, Preskorn SH. Treatment of Depressive Disorders in Elderly Complicated with Medical Co-morbidities and Multiple Medication Use. In: Herrman H, Santorius N, Editors. *Depressive Disorders*, M.M. John Wiley & Sons, Ltd.: Hoboken, NJ. 2009; 268-270
- (49) D'Empaire I, Preskorn SH. New Evidence and Caution. In: Herrman H, Santorius N, Editors. *Depressive Disorders*, M.M. John Wiley & Sons, Ltd. Hoboken, NJ. 2009; 86-87
- (50) Dahmen, MM, Lincoln J, Preskorn S. NARI Antidepressants. *Encyclopedia of Psychopharmacology: NARI Antidepressants*. Berlin Heidelberg :Springer-Verlag 2010 DOI 10.1007/978-3-540-68706-1.
- (51) Macaluso M, Preskorn SH. Drug to Drug Interactions and Selective Serotonin Reuptake Inhibitors. In: *Pharmacological Interactions with Psychiatric Drugs*. AC Pharmaceutica. 2011 [This book has been translated in Spanish and Portuguese.]
- (52) Preskorn, SH. History of CNS drug development. In Kalali A, Preskon S, Kwentus J, and Stahl S, Editors. *Essential CNS Drug Development*. Cambridge University Press, New York, 2012, pp 1-14
- (53) Macaluso M, Krams M, Preskorn SH. Phase I trials: from traditional to newer approaches. In Kalali A, Preskon S, Kwentus J, and Stahl S, Editors. *Essential CNS Drug Development*. Cambridge University Press, New York, 2012, pp 55 - 70
- (54) Khan A, Preskorn S: Multiple Psychiatric Medications Use in Psychiatry: How Rational Can It Be? In Ritsner M, Editor. *Polypharmacy in Psychiatric Practice*. Heidelberg: Springer-Verlag.
- (55) D'Empaire I, Preskorn SH, Macaluso M. Use of Laboratory in Psychiatry. Chapter in: *The Medical Basis of Psychiatry*. 4th edition. April 2016. Springer. ISBN: 978-1-4939-2527-8 (Print) 978-1-4939-2528-5
- (56) Macaluso M, Preskorn S. (2017). Pharmacogenomics. In A. Wenzel (Ed.), *The SAGE Encyclopedia of Abnormal and Clinical Psychology* (pp. 2575). Thousand Oaks, CA: SAGE Publications, Inc.
- (57) Macaluso M, Krams M, Savitz J, Drevets W, Preskorn S: *New Approaches in Translational Medicine for Phase I Clinical Trials of CNS Drugs in Translational Medicine in CNS Drug Development* edited by George Nomikos and Douglas Feltner, Elsevier, 2018

Books:

- (1) Balderessarini R, Cole J, David J, Gardos G, Preskorn SH, Simpson G et al. Tardive dyskinesia: A task force report. *Am J Psychiatry* 1980; 137(10):1163-1172.
- (2) Janicak P, Davis J, Preskorn SH, Ayd Jr. F. Principles and Practice of Psychopharmacotherapy. 1st ed. Baltimore: Williams & Wilkins, 1993.
- (3) Preskorn SH. Outpatient management of depression. 1st ed. Caddo, Oklahoma: Professional Communications, Inc., 1994.
- (4) Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors. 1st ed. Caddo, OK.: Professional Communications, Inc., 1996.
- (5) Janicak P, Davis JM, Preskorn SH, Ayd Jr FJ. Principles and practice of psychopharmacotherapy. 2nd ed. Baltimore: Williams & Wilkins, 1997.
- (6) Preskorn SH. Outpatient Management of Depression. 2nd ed. Caddo: Professional Communications, Inc., 1999.
- (7) Janicak P, Davis JM, Preskorn SH, Ayd Jr. FJ. Principles and Practices of Psychopharmacotherapy. 3rd ed. Philadelphia: Lippincott Williams and Wilkins, 2001.
- (8) Preskorn SH, Feighner JP, Stanga CY, Ross R. Handbook of Experimental Pharmacology Antidepressants: Past, Present, and Future. Heidelberg: Springer-Verlag, 2004.
- (9) Preskorn SH, Flockhart DA. Psychotropic drug Interactions Guide. New York: MBL Communications, 2004.
- (10) Janicak PG, Davis JM, Preskorn SH, Ayd FJ, Jr., Marder SR, Pavuluri MN. Principles and practice of psychopharmacology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006
- (11) Preskorn SH. Outpatient Management of Depression. 3rd ed. Caddo: Professional Communications, Inc., 2009.
- (12) Kalali A, Preskon S, Kwentus J, and Stahl S: Essential CNS Drug Development. Cambridge University Press, New York, 2012
- (13) Preskorn S: Drug-Drug Interactions With an Emphasis on Psychiatric Medications. Professional Communications, Inc., 2018

Abstracts:

- (1) Preskorn SH, Lewis G. Acetylcholine: General cortical activity vs. stimulus-response. *Proceedings of Kansas Psychological Society* 14[25]. 1970.
- (2) Lewis G, Preskorn SH, Hughes C. The effect of electrical brain stimulation during early development on biochemical and behavioral measures later in life. *Proceedings of Southwest Psychological Association* 12, 270. 1971.
- (3) Preskorn SH, Edwards WD. Microwave fever and experimental sarcoma in mice. *Clinical Research* 22, 673A. 1974.
- (4) Watanabe I, Preskorn SH, Matovich V, Rengarchary S, Sato T. Demyelinating changes in the Schmidt-Lanterman cleft. *J Neuropathol Exp Neurol* 34, 103. 1975.
- (5) Preskorn SH, Kepes J, Bopp W, Watanabe I. Propagation of JC virus in glial cells in PML. *Proceedings of the Electron Microscopic Society of America* 33, 328. 1975.
- (6) Preskorn SH, Denner L. Benzodiazepines sudden withdrawal can elicit psychotic reaction. *Modern Medicine* 30, 83. 1977.

- (7) Preskorn SH, Clark H, Hartman B, Raichle M. Amitriptyline-induced alterations in cerebral capillary permeability. *Society for Neuroscience Abstracts* 4, 500. 1978.
- (8) Hughes C, Preskorn SH, Hartman B, Veit P. Comparison of behavioral effects of 6-hydroxydopamine, reserpine and tetrabenzamine. *Society for Neuroscience Abstracts* 5, 649. 1979.
- (9) Preskorn SH, Alward P. The effect of amitriptyline on brain ethanol concentrations. *Society of Neuroscience Abstracts* 5, 659. 1979.
- (10) Irwin G, Preskorn SH. Simultaneous measurement of brain permeability and blood flow in the rat. *Society for Neuroscience Abstracts* 6, 829. 1980.
- (11) Cantilena Jr LR, Irwin G, Preskorn SH, Klassen CD. The effect of diethyldithiocarbamate on brain uptake of cadmium. *Toxicol Appl Pharmacol* 1982; 63(3):338-343.
- (12) Preskorn SH, Hartman B, Hughes C, Clark H, Irwin G. 6-Hydroxydopamine ablation of amitriptyline-induced alteration in blood-brain barrier. *Society for Neuroscience Abstracts* 6, 831. 1980.
- (13) Kent T, Preskorn SH. Tetrabenzamine model of depression: Changes in cerebral fluid dynamics. *Society for Neuroscience Abstracts* 7, 512. 1981.
- (14) Winsky R, Preskorn SH, Glotzbach R, Irwin G. Novel antidepressants and neuroleptics: Effect on the central adrenergic system. *Society for Neuroscience Abstracts* 7, 644. 1981.
- (15) Solnik J, Kent T, Preskorn SH, Irwin G. Biogenic amine depletion alter cerebrocirculation. *Society for Neuroscience Abstracts* 8, 850. 1982.
- (16) Weller E, Weller R, Preskorn SH. Plasma imipramine levels and clinical response in depressed children. *Clin Pharmacol Ther* 31, 280. 1982.
- (17) Irwin G, Stewart D, Reimold M, Crumpacker J, Kruse M, Preskorn SH. Blood-brain barrier permeability to water measured by a dual-isotope, single transit technique: Effect of altered plasma osmolality. *Society for Neuroscience Abstracts* 8, 849. 1982.
- (18) Weller E, Preskorn SH, Weller R. Childhood depression: Imipramine levels and response. *Clin Pharmacol Ther* 31, 280. 1982.
- (19) Weller R, Glotzbach R, Preskorn SH. Brain concentrations of tricyclic antidepressants: Kinetics and dynamics. *Clinical Research* 30, 814A. 1982.
- (20) Preskorn SH, Othmer S, Lai C, Othmer E, Kent T. EEG abnormalities due to high antidepressant level. *Clin Pharmacol Ther* 33, 242. 1983.
- (21) Weller E, Weller R, Glotzbach E, Preskorn SH. Plasma levels of imipramine and adverse effects in children. *Clin Pharmacol Ther* 33, 247. 1983.
- (22) Hughes C, Kent T, Campbell J, Preskorn SH. Effects of inescapable shock on cerebral blood flow and cerebrovascular permeability in rats. *Society for Neuroscience Abstracts* 9, 562. 1983.
- (23) Swartzman J, Preskorn SH, Kent T, Goldberg S, Glotzbach E. Effects of different classes of psychopharmaceuticals on cerebral capillary permeability and blood flow. *Society for Neuroscience Abstracts* 9, 157. 1983.
- (24) Kent T, Nagy G, Oke A, Preskorn SH, Adams R. Modification of brain extracellular space by CO₂: Neural regulation. *Society for Neuroscience Abstracts* 9, 887. 1983.
- (25) Oke A, Kent T, Preskorn SH, Adams R. *In vivo* electrochemical detection of the effects of CO₂ on biogenic amine release. *Society for Neuroscience Abstracts* 9, 1002. 1983.
- (26) Preskorn SH, Bupp SJ, Croskell M, Croskell H. Battleboro rats demonstrate normal cerebrocirculatory responsiveness to alteration in arterial CO₂. *Society for Neuroscience Abstracts* 13, 773. 1987.
- (27) Preskorn SH, Dorey RC, Jerkovich GS, Widener PK. Tricyclic antidepressants: Therapeutic drug monitoring. *MIND* 2[5], 8-10. 1988.

- (28) Preskorn SH. Central nervous system toxicity of tricyclic antidepressants: A case report. *MIND* 5[2], 7. 1988.
- (29) Drevets WC, Raichle ME, Fox PT, Preskorn SH, Videan TO. Trait and state cerebral blood flow abnormalities in depression. *Society for Neuroscience Abstracts* 15[1], 30. 1989.
- (30) Preskorn SH, Swartman J. Mianserin alters cerebromicrocirculatory responsivity to changes in arterial CO₂. *Society for Neuroscience Abstracts* 15, 1220. 1989.
- (31) Preskorn SH, Watanabe I, Dick A, Henson SR. Amitriptyline effect on brain fluid dynamics. *Society for Neuroscience Abstracts* 15, 1220. 1989.
- (32) Horst WD, Stucky C, Widener P, Castellani S, Preskorn SH. Evaluation of a receptor binding assay for determining anticholinergic drug levels in plasma. *Society for Neuroscience Abstracts* 15, 1236. 1989.
- (33) Goldstein E, Preskorn SH, Silkey B, Haug L. A comparison of chronic schizophrenics with interictal psychosis. *Society for Neuroscience Abstracts* 16, 876. 1990.
- (34) Cranford J, Goldstein E, Preskorn SH, Moore C. Effects of temporal lobe lesions on the precedence effect in sound localization. *Society for Neuroscience Abstracts* 16, 1350. 1990.
- (35) Preskorn SH. Therapeutic drug monitoring of antidepressants in practice. *Clinical Neuropharmacology* 13(2), 565. 1990.
- (36) Preskorn SH. Cardiovascular and central nervous system toxicity of antidepressants. *Clinical Neuropharmacology* 15[suppl 1, Part A], 290A-291A. 1992.
- (37) Preskorn SH, von Moltke L, Chung M, Messig M, Alderman J, Greenblatt DJ et al. Interaction between fluoxetine or sertraline and desipramine, *in vitro* and *in vivo* evaluation in human tissue and subjects. *Psychopharmacol Bull* 30(1), 121. 1994.
- (38) Preskorn SH. Pharmacotherapeutic profile of venlafaxine. *Eur Neuropsychopharmacol* 5(3), 251-252. 1995.
- (39) Preskorn SH. Tansospirone: A viewpoint. *CNS Drugs* 1996; 5(2):154.
- (40) Preskorn SH, Harvey AT. Biochemical and clinical dose-response curves with sertraline. *Clin Pharmacol Ther* 59[2], 180. 1996.
- (41) Preskorn SH. Pharmacology and the relevance for choice. *Eur Neuropsychopharmacol* 6[S4], 63. 1996.
- (42) Harvey AT, Preskorn SH. Mechanism of action of venlafaxine in normal male volunteers. *Clin Pharmacol Ther* 61[2], 175. 1997.
- (43) Preskorn SH, Shad MU, Alderman J, Lane R. Fluoxetine: Age and dose dependent pharmacokinetics and CYP 2C19 inhibition. *Clinical Pharmacol Ther* 63[2], 166. 1998.
- (44) Shad MU, Preskorn SH, Miceli J, Wilner K. Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients. *Clin Pharmacol Ther* 65, 171. 1999.
- (45) Shad MU, Carmichael CA, Preskorn SH, Horst WD. The nature and extent of polypharmacy in patients on antidepressants as a function of treatment setting. *Clin Pharmacol Ther* 65, 183. 1999.
- (46) Preskorn SH. Pharmacogenetic research in clinical psychopharmacology: Design and methodological challenges. *Int'l J Neuropsychopharmacology* 3[suppl 1], S5. 2000.
- (47) Silkey B, Preskorn SH, Golbeck A, Horst WD. Addressing health risks/costs associated with multiple medication use in a veterans integrated service network. 2000. *Drug Information Association 2nd Annual Workshop on "Pharmaceutical Outcomes Research"*.
- (48) Silkey B, Preskorn SH, Golbeck A. Interindividual variability in steady-state plasma levels of bupropion and its major metabolites. 2000. 40th Annual *NCDEU*.
- (49) Harvey AT, Preskorn SH. The influence of extended-release venlafaxine on QT intervals of normal volunteers. 2001. 41st *NCDEU*

- (50) Khan AY, Friesen S, Klick-Davis A, Preskorn SH. How inclusion and exclusion criteria affect the ability to randomize patients in a clinical trial for schizophrenia/schizo-affective disorder. 2001. 41st NCDEU, Phoenix, AZ.
- (51) Preskorn SH, Baker B. The clinical pharmacology of antidepressants: Relevance to the optimum management of the depressed patient. *AANP* . 2001.
- (52) Harvey AT, Preskorn SH. The influence of intramuscular (IM) haloperidol (HAL) or lorazepam (LOR) on QT intervals of volunteers with schizophrenia. *Clin Pharm and Ther* 71[2], P53. 2002
- (53) Preskorn SH, Silkey B, Shah R, Neff M. Multiple medication use and cytochrome P-450 based drug interaction patterns in patients on antidepressants in a regional veterans affairs health care network. *Clin Pharm Ther* 71[2], 59. 2002
- (54) Wesnes, K.A., Preskorn, S.H., Friesen, S., Edgar, C., and Mikkelsen, B.O. NS 2330 enhances cognitive function in normal volunteers and volunteers with possible Alzheimer's Disease (AD). *Clin Pharm Ther* 71:17. 2002
- (55) Khan AY, Preskorn SH. Pharmacokinetic principles and drug interactions. Handbook of medical psychiatry. 945-944. 2003
- (56) Preskorn SH, Shah R, Silkey B, Neff M, Golbeck A, Choi J. The potential for clinically significant drug-drug interactions in patients receiving CYP 2D6 model substrate/drugs and fluoxetine/paroxetine or sertraline. *Clin Pharm Ther* 75[2], 71. 2004.
- (57) Preskorn SH. Comorbidity polypharmacy and CYP enzymes: What have we learned in terms of safety. *World J Biol Psychiatry* 5 [suppl 1]:32. 2004
- (58) Preskorn SH, Baker B, Klick-Davis A *et al*. The effect of duloxetine, escitalopram, and sertraline on CYP 2D6 function. *Clin Pharm Ther* 79(2):52. 2006
- (59) Preskorn SH, Lombardo I, Alderman J, Wilner K., Miceli J. Effect of Food on Absorption of Ziprasidone. *Clinical Pharmacology & Therapeutics* 81:S82. 2007
- (60) Ong VS, Deng C, Murray M, Lowe D, Kittrelle J, Preskorn SH. Lack of Hemodynamic Effect of MEM 1003, A Dihydropyridine Calcium-Channel Blocker: An Exposure-Safety Relationship Assessment. *Clinical Pharmacology & Therapeutics* 81:S64. 2007
- (61) Preskorn SH, Patroneva A, et al. A comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine succinate in healthy subjects. *The Journal of the European College of Neuropsychopharmacology* 17(4): S339. 2007
- (62) Preskorn S, Chapel S, et al. Effect of asenapine versus quetiapine and placebo on QTc interval in patients with schizophrenia. *The Journal of the European College of Neuropsychopharmacology* 17 (4): S453-454. 2007.
- (63) Preskorn S, Lombardo I, et al. Effect of meal size and fat content on oral ziprasidone absorption. *The Journal of the European College of Neuropsychopharmacology* 17 (4): S463-464. 2007
- (64) R Burch, S Preskorn, L Bastin, W Yu, J Burgdorf, J Moskal : Adjunctive GLYX-13 Induces Prolonged Efficacy in Subjects with Major Depressive Disorder (MDD) *Neuropsychopharmacology* 39, S335-S335, 2014
- (1) Valuck
- (2) Valuck

Poster presentations - only posters which has not yet been published are listed below:

- (1) Savitz JB, Teague TK, Wurfel B, Meyer M, Macaluso M, Drevets D, Yates W, Gleason O, Drevets WC, Preskorn SH. Treatment of Bipolar Depression with Minocycline and/or Aspirin: An adaptive, double-blind,

randomized, placebo-controlled clinical trial (NCT01429272). Poster Presented at the American College of Neuropsychopharmacology Annual Meeting. Miami, FL (12/2015)

(2) Coulson A, Macaluso M, Wurfel B, Savitz J, Meyer M, Drevets WC, Preskorn SH, "Determining and Addressing Recruitment Challenges in Bipolar Disorder, Depressed Phase. Poster presented at the Annual Meeting of the American Society of Clinical Psychopharmacology. Miami, FL (6/22/15).

(3) Kazanchi HZ, Macaluso M, Preskorn SH, "Understanding the Pharmacodynamic and Pharmacokinetic Differences of Various Newer Antipsychotics." Poster presented at KUSM-W Research Forum, Wichita, KS (4/29/15).

Letters to the Editor:

- (1) Preskorn SH, Biggs JT. Use of tricyclic antidepressant blood levels. *N Engl J Med* 1978; 298(3):166.
- (2) Preskorn SH, Madakasira S. Drug monitoring and improved treatment response. *Am J Psychiatry* 1980; 137(12):1622-1623.
- (3) Preskorn SH. A flawed design. *J Clin Psychiatry* 1982; 43:389-390.
- (4) Preskorn SH. Use of plasma levels to avoid amitriptyline toxicity. *J Clin Psychiatry* 1983; 44(11):430.
- (5) Jerkovich G, Preskorn SH. Failure of buspirone to protect against lorazepam withdrawal symptoms. *JAMA* 1987; 258(2):204-205.
- (6) Preskorn SH, Weller E, Hughes C, Weller R. Relationship of plasma imipramine levels to CNS toxicity in children. *Am J Psychiatry* 1988; 145(7):897.
- (7) Goldman D, Katz S, Preskorn SH. What to do about extremely high plasma levels of tricyclics? *Am J Psychiatry* 1989; 146(3):401-402.
- (8) Hon D, Preskorn SH. Mania during fluoxetine treatment for recurrent depression. *Am J Psychiatry* 1989; 146(12):1638-1639.
- (9) Goldstein E, Preskorn SH. Mania triggered by a steroid nasal spray in a patient with stable bipolar disorder. *Am J Psychiatry* 1989; 146(8):1076-1077.
- (10) Preskorn SH, Beber JH, Faul JC, Hirschfeld RMA. Serious adverse effects of combining fluoxetine and tricyclic antidepressants. *Am J Psychiatry* 1990; 147(4):532.
- (11) Preskorn SH, Fleck R, Schroeder D. Therapeutic drug monitoring of bupropion. *Am J Psychiatry* 1990; 147(12):1690.
- (12) Preskorn SH, Fast GA. Drs. Preskorn and Fast reply. *J Clin Psychiatry* 1993; 54(5):201-202.
- (13) Preskorn SH. Therapeutic drug monitoring with tricyclic antidepressants: A response. *J Clin Psychopharmacol* 1994; 14, No. 4.
- (14) Burke M, Preskorn SH. Sertraline and hepatic metabolism. *Consultant Pharmacists* 1994; 9:837.
- (15) Harvey AT, Preskorn SH. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. *Arch Gen Psychiatry* 1995; 52:783-784.
- (16) Lacey R, Preskorn SH, Jerkovich G. Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics? *Am J Psychiatry* 1995; 152(9):1401.
- (17) Preskorn SH. Drug-drug interactions. *J Clin Psychiatry* 1996; 57(5):223-225.
- (18) Burke M, Harvey AT, Preskorn SH. Pharmacokinetics of the newer antidepressants. *Am J Med* 1996; 100:119-120.

- (19) Preskorn SH, Baker B. Fatality associated with combined fluoxetine-amitriptyline therapy. *JAMA* 1997; 277(21):682.
- (20) Shad MU, Preskorn SH. A possible bupropion and imipramine interaction. *J Clin Psychopharmacol* 1997; 17(2):118-119.
- (21) Shad MU, Preskorn SH. Pharmacodynamic and pharmacokinetic factors in a case of neuroleptic malignant syndrome. *J Clin Psychopharmacol* 1998; 18(4):346-347.
- (22) Shad MU. Drug-drug interaction in reverse: Possible loss of phenytoin efficacy as a result of fluoxetine discontinuation. *J Clin Pharmacol* 1999; 19(5):471-472.
- (23) Shad MU, Preskorn SH, Izzur Z. Failure to consider drug-drug interactions as a likely cause of behavioral deterioration in a patient with bipolar disorder. *J Clin Psychiatry* 2000; 20(3):390-392.
- (24) Khan AY, Shad MU, Preskorn SH. Lack of sertraline efficacy probably due to an interaction with carbamazepine. *J Clin Psychiatry* 2000; 61(7):526-527.
- (25) Preskorn SH, Greenblatt DJ, Harvey AT. Lack of effect of sertraline on the pharmacokinetics of alprazolam. *Journal of Clinical Psychopharmacology* 2000; 20(5):585-586.
- (26) Khan AY, Preskorn SH. Increase in plasma levels of clozapine and norclozapine after administration of nefazodone. *J Clin Psychiatry* 2001; 62(5):375-376.
- (27) Preskorn SH: Dr Preskorn replies. *J Clin Psychiatry*. 2013 Oct;74(10):1025-6. (PMID: 24229758)

EDITOR OF JOURNAL SUPPLEMENTS:

- (1) Clinical crossfire: Pharmacokinetics and psychiatric drugs. *Journal of Clinical Psychiatry*, 54(suppl), 1993.
- (2) Factors to consider in selecting an antidepressant. *J of Clinical Psychiatry*, 55 (SupA) 1994
- (3) Interaction Profile of Sertraline with commonly prescribed medications. *Journal of Clinical Psychiatry*, 57(suppl 1), 1996.
- (4) Sertraline: A pharmacokinetic profile. *Journal of Clinical Pharmacokinetics*. 32(S1), 1997

EDITOR NPL Facts Newsletter:

- (1) Preskorn SH. The laboratory in psychiatry: Monitoring tricyclic antidepressants:An introduction. *NPL Facts Newsletter* 1990; 1(1):1-4.
- (2) Preskorn SH. The laboratory in psychiatry: Monitoring tricyclic antidepressants:Avoiding CNS toxicity. *NPL Facts Newsletter* 1990; 1(2):1-4.
- (3) Preskorn SH, Fast GA. The laboratory in psychiatry: monitoring tricyclic antidepressants: avoiding cardiac toxicity. *NPL Facts Newsletter* 1991; 1(3):1-5.
- (4) Preskorn SH, Fast F. The laboratory in psychiatry: monitoring tricyclic antidepressants: improving antidepressant efficacy and cost effectiveness. *NPL Facts Newsletter* 1991; 1(4):1-5.
- (5) Preskorn SH. Therapeutic drug monitoring of bupropion and its metabolites: a way of increasing the drug's safe and effective use? *NPL Facts Newsletter* 1992; 1(5):1-4.
- (6) Preskorn SH. Pharmacokinetics and good clinical practice: basic principles. *NPL Facts Newsletter* 1993; 1(7):1-4.

Published Interviews:

- (1) Preskorn SH. An approach to therapeutic drug monitoring (published interview). *Currents in Affective illness* 1988; 7(10):5-13.
- (2) Preskorn SH. Tricyclic antidepressants: The whys and hows of therapeutic drug monitoring. *J Clin Psychiatry* 1989; 50[suppl 7]:34-42.
- (3) Preskorn SH. Selected topics on the pharmacokinetics and drug interactions of selective-serotonin reuptake inhibitors. *Currents in Affective illness* 1992; 11(2):5-12.
- (4) Preskorn SH. Hidden treasure. Schneidler K, editor. *Wichita Eagle* . 5-13-1996. Wichita.
- (5) Preskorn SH. Men's Journal. 86-87. 1996. Jannot, M.
- (6) Preskorn SH. Drug interactions with SSRIs: Are they a concern? *Curr Issues Depression* . 1996. St. Leonards.
- (7) Preskorn SH. Pharmacokinetic interactivity of psychotropic drugs: Part I. Rosenblatt JE, Rosenblatt NC, editors. *Curr Affect Illness* 17[4]. 1998.
- (8) Preskorn SH. Pharmacokinetic interactivity of psychotropic drugs: Conclusion. Rosenblatt JE, Rosenblatt NC, editors. *Curr Affect Illness* 17[5]. 1998.
- (9) Preskorn SH. New paradigms for drug development: Part I. *Curr in Affective illness* 2001; 20(3):5-15.
- (10) Preskorn SH. New paradigms for drug development: Part 2. *Curr in Affective illness* 2001; 20(4):5-15.
- (11) Preskorn SH. Polypharmacy of psychotropic drugs. PAREXEL, editor. *Ment Health Issues Today* 6[3]. 2003. Centreville.

PSYCHIATRY VIDEOTAPES:

1. Preskorn SH. Antipsychotics. 55 minutes, 1986.
2. Preskorn SH. Antidepressants. 55 minutes, 1986.
3. Preskorn SH. Benzodiazepines. 55 minutes, 1986.
4. Preskorn SH. Benzodiazepines: Abuse and withdrawal liabilities. 30 minutes, 1986.
5. Podrebara F, Preskorn SH. The mental status examination, 55 minutes. 1987.
6. Henson S, Preskorn SH. Bipolar disorder: Before and after treatment. 37 minutes, 1988.
7. Henson S, Preskorn SH. Antisocial personality disorder/somatization disorder. 35 minutes, 1989.
8. Preskorn SH. Antidepressants, revised, 55 minutes, 1990.
9. Crisp-Lindgren N, Preskorn SH. Positive and negative symptoms of schizophrenia: Case examples. 37 minutes, 1990.
10. Preskorn SH. Masques of melancholia: An evening of drama and literature. A clinical discussion of issues involving the diagnosis and treatment of depression. 1992.
11. Rains J, Preskorn SH. The young mania rating scale. 1993.
12. Preskorn SH. Clinical crossfire: Pharmacokinetics and psychiatric drugs. 19 minutes. 1993.
13. Koch J, Preskorn SH. Memory loss and aging: Is it Alzheimer's? 1 hour 54 minutes. 1994.

14. Preskorn SH. Clinical crossfire: Pharmacokinetics and psychiatric drugs. 19 minutes. 1993.
15. Koch J, Preskorn SH. Memory loss and aging: Is it Alzheimer's. 1 hour 54 minutes. 1994.
16. Preskorn SH. Pharmacodetectives: Case histories of antidepressant therapy. 23 minutes. 1995.
17. Preskorn SH. Clinical importance of the cytochrome P450 system in psychiatry. 22 minutes. 1995
18. Preskorn SH. Issues in primary care drug interactions and treatment of depression. 1996.
19. Preskorn SH. Selegiline patch depression with Sahar El-Hodiri. 1997

SLIDE KITS:

1. Preskorn S: Antidepressant update: Pharmacokinetics, pharmacology, and clinical experience. The Medicine Group, Toronto, 1994.
2. Preskorn S: Advances in antidepressant therapy: The pharmacological basis. Professional Communications, Inc., Caddo, 1994.
3. Preskorn S: The clinically relevant pharmacology of the SSRIs: Pharmacology and Pharmacokinetics, 1994.
4. Preskorn S: Pharmacokinetics and psychiatric medicine: Optimizing efficacy, safety, and cost effectiveness. Current Medical Directions, New York, 1997.

PUBLIC AFFAIRS:

1. Medical Advisor, "The Kansas Mental Illness Test," a prime time one hour television program for Mental Illness Awareness Week, 1989.
2. Medical Advisor, "Beating the Blues," a week long television news series for Mental Illness Awareness Week, 1990.
3. Medical Advisor, "The facts and faces of mental illness: A mental health brochure for the 1990s," developed in conjunction with Roerig-Pfizer Pharmaceutical Co. and distributed state-wide for Mental Illness Awareness Week, 1990.
4. "Live at Five". An interview on prime time one-hour television program for Mental Awareness Week, 1996.
5. "Mike and Mogie Show". An interview on prime time television, re: Childhood and Adolescent Depression, April, 1996.
6. "Opinion Newsletter". An interview for psychiatrists abroad, re: Challenges in the pharmacologic treatment of depression. 1996.
7. Preskorn S: Alzheimer's vascular dementia. KSNW-3, noon call in. October 14, 1996
8. "Live at Five". An interview on prime time television concerning depression in general, November, 1997.
9. "Family Health Channel, Focus on Depression." An interview concerning depression, 1998.

SPECIAL PRESENTATIONS:

1. 1997- University of Toronto in Toronto, Ontario, Canada
2. Visiting Professor for Annual Psychopharmacology Day:

3. 1999- University of Hamilton in Hamilton, Ontario, Canada
4. 1998- University of Alberta in Edmonton, Alberta, Canada
5. Sept. 14, 2002 – German Neuroscience Academy in Versailles, France. “Drug development in psychiatry and the human genome project: Implications for clinical practice.”
6. Oct. 6, 2002 – Keynote address at Annual Psychopharmacology Update Program for the University of Mississippi in Jacksonville, MS. “The rational basis for the combined use of more than one psychiatric medication.”
7. Oct. 2, 2002 – Keynote address at Annual Psychopharmacology Update Program for the University of Oklahoma at Tulsa. “Drug-drug interactions: Their mechanisms, their clinical presentation, and their clinical relevance.”
8. Nov. 19, 2009 - Visiting Professor at University of Toronto General Hospital
9. Sept. 9, 2016 – Invited seminar (3.5 hours) to the FDA Office of Clinical Pharmacology, Washington D.C.
10. Oct. 6, 2016 – Eli Robins Lectureship in Psychiatry at Washington University, St. Louis MO.
11. Oct. 8, 2016 – First Annual Henry & Amelia Lecture in Psychiatry at St. Louis University, St. Louis MO.